• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 10-Q filed by Mannatech Incorporated

    11/12/25 4:03:53 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MTEX alert in real time by email
    mtex20250930_10q.htm
    0001056358 MANNATECH INC false --12-31 Q3 2025 783 935 0.01 0.01 1,000,000 1,000,000 0 0 0 0 0.0001 0.0001 99,000,000 99,000,000 2,742,857 1,900,930 2,742,857 1,884,814 841,927 858,043 3 0.1 2.9 0 0 0 2 3 10 5 0.2 0 0 0 0 0 0 0 5 0 1 25 false false false false Approximately $13,000 and $6,000 of associate fees are included in total sales, for the three months ended September 30, 2025 and 2024, respectively. Approximately $19,000 and $13,000 of associate fees are included in total sales, for the nine months ended September 30, 2025 and 2024, respectively. 00010563582025-01-012025-09-30 xbrli:shares 00010563582025-11-04 thunderdome:item iso4217:USD 00010563582025-09-30 00010563582024-12-31 iso4217:USDxbrli:shares 00010563582025-07-012025-09-30 00010563582024-07-012024-09-30 00010563582024-01-012024-09-30 0001056358mtex:CommonStockOutstandingMember2024-12-31 0001056358us-gaap:AdditionalPaidInCapitalMember2024-12-31 0001056358us-gaap:RetainedEarningsMember2024-12-31 0001056358us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-31 0001056358us-gaap:TreasuryStockCommonMember2024-12-31 0001056358mtex:CommonStockOutstandingMember2025-01-012025-03-31 0001056358us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-31 0001056358us-gaap:RetainedEarningsMember2025-01-012025-03-31 0001056358us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-31 0001056358us-gaap:TreasuryStockCommonMember2025-01-012025-03-31 00010563582025-01-012025-03-31 0001056358mtex:CommonStockOutstandingMember2025-03-31 0001056358us-gaap:AdditionalPaidInCapitalMember2025-03-31 0001056358us-gaap:RetainedEarningsMember2025-03-31 0001056358us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-31 0001056358us-gaap:TreasuryStockCommonMember2025-03-31 00010563582025-03-31 0001056358mtex:CommonStockOutstandingMember2025-04-012025-06-30 0001056358us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-30 0001056358us-gaap:RetainedEarningsMember2025-04-012025-06-30 0001056358us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-30 0001056358us-gaap:TreasuryStockCommonMember2025-04-012025-06-30 00010563582025-04-012025-06-30 0001056358mtex:CommonStockOutstandingMember2025-06-30 0001056358us-gaap:AdditionalPaidInCapitalMember2025-06-30 0001056358us-gaap:RetainedEarningsMember2025-06-30 0001056358us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-30 0001056358us-gaap:TreasuryStockCommonMember2025-06-30 00010563582025-06-30 0001056358mtex:CommonStockOutstandingMember2025-07-012025-09-30 0001056358us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-30 0001056358us-gaap:RetainedEarningsMember2025-07-012025-09-30 0001056358us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-07-012025-09-30 0001056358us-gaap:TreasuryStockCommonMember2025-07-012025-09-30 0001056358mtex:CommonStockOutstandingMember2025-09-30 0001056358us-gaap:AdditionalPaidInCapitalMember2025-09-30 0001056358us-gaap:RetainedEarningsMember2025-09-30 0001056358us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-09-30 0001056358us-gaap:TreasuryStockCommonMember2025-09-30 0001056358mtex:CommonStockOutstandingMember2023-12-31 0001056358us-gaap:AdditionalPaidInCapitalMember2023-12-31 0001056358us-gaap:RetainedEarningsMember2023-12-31 0001056358us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-31 0001056358us-gaap:TreasuryStockCommonMember2023-12-31 00010563582023-12-31 0001056358mtex:CommonStockOutstandingMember2024-01-012024-03-31 0001056358us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-31 0001056358us-gaap:RetainedEarningsMember2024-01-012024-03-31 0001056358us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-31 0001056358us-gaap:TreasuryStockCommonMember2024-01-012024-03-31 00010563582024-01-012024-03-31 0001056358mtex:CommonStockOutstandingMember2024-03-31 0001056358us-gaap:AdditionalPaidInCapitalMember2024-03-31 0001056358us-gaap:RetainedEarningsMember2024-03-31 0001056358us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-31 0001056358us-gaap:TreasuryStockCommonMember2024-03-31 00010563582024-03-31 0001056358mtex:CommonStockOutstandingMember2024-04-012024-06-30 0001056358us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-30 0001056358us-gaap:RetainedEarningsMember2024-04-012024-06-30 0001056358us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-30 0001056358us-gaap:TreasuryStockCommonMember2024-04-012024-06-30 00010563582024-04-012024-06-30 0001056358mtex:CommonStockOutstandingMember2024-06-30 0001056358us-gaap:AdditionalPaidInCapitalMember2024-06-30 0001056358us-gaap:RetainedEarningsMember2024-06-30 0001056358us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-30 0001056358us-gaap:TreasuryStockCommonMember2024-06-30 00010563582024-06-30 0001056358mtex:CommonStockOutstandingMember2024-07-012024-09-30 0001056358us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-30 0001056358us-gaap:RetainedEarningsMember2024-07-012024-09-30 0001056358us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-30 0001056358us-gaap:TreasuryStockCommonMember2024-07-012024-09-30 0001056358mtex:CommonStockOutstandingMember2024-09-30 0001056358us-gaap:AdditionalPaidInCapitalMember2024-09-30 0001056358us-gaap:RetainedEarningsMember2024-09-30 0001056358us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-30 0001056358us-gaap:TreasuryStockCommonMember2024-09-30 00010563582024-09-30 xbrli:pure 0001056358us-gaap:OtherInvesteesMember2025-09-30 0001056358us-gaap:OtherInvesteesMember2024-12-31 0001056358mtex:LoyaltyProgramMember2025-09-30 0001056358mtex:LoyaltyProgramMember2024-09-30 0001056358mtex:JadeCapitalMembermtex:DebtInstrumentUnsecuredNotesPayableMember2024-04-23 0001056358mtex:JadeCapitalMembermtex:DebtInstrumentUnsecuredNotesPayableMember2025-09-30 0001056358mtex:JStanleyFrederickMembermtex:DebtInstrumentUnsecuredNotesPayableMember2024-04-23 0001056358mtex:JStanleyFrederickMembermtex:DebtInstrumentUnsecuredNotesPayableMember2025-09-30 0001056358mtex:KevinRobbinsMembermtex:DebtInstrumentUnsecuredNotesPayableMember2024-04-23 0001056358mtex:KevinRobbinsMembermtex:DebtInstrumentUnsecuredNotesPayableMember2025-09-30 0001056358mtex:JadeCapitalMember2025-09-30 0001056358mtex:JStanleyFrederickMember2025-09-30 0001056358mtex:KevinRobbinsMember2025-09-30 0001056358mtex:The2017StockIncentivePlanMember2017-04-17 0001056358mtex:The2017StockIncentivePlanMember2025-09-30 utr:Y 0001056358us-gaap:EmployeeStockOptionMembermtex:The2017StockIncentivePlanMembersrt:MinimumMember2017-04-172017-04-17 0001056358us-gaap:EmployeeStockOptionMembermtex:The2017StockIncentivePlanMembersrt:MaximumMember2017-04-172017-04-17 0001056358us-gaap:EmployeeStockOptionMembermtex:The2017StockIncentivePlanMember2017-04-172017-04-17 0001056358mtex:IncentiveOptionMembermtex:The2017StockIncentivePlanMember2017-04-172017-04-17 0001056358mtex:The2017StockIncentivePlanMember2025-01-012025-09-30 0001056358mtex:The2017StockIncentivePlanMember2024-01-012024-09-30 0001056358us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2024-03-112024-03-11 utr:M 0001056358us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2024-03-11 0001056358us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2025-09-30 0001056358us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2025-07-012025-09-30 0001056358us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2025-01-012025-09-30 0001056358srt:ScenarioForecastMember2026-12-31 0001056358srt:ScenarioForecastMember2027-12-31 0001056358srt:DirectorMember2025-01-012025-09-30 0001056358srt:DirectorMember2024-01-012024-09-30 0001056358us-gaap:AccumulatedTranslationAdjustmentMember2024-12-31 0001056358us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-12-31 0001056358us-gaap:AccumulatedTranslationAdjustmentMember2025-01-012025-09-30 0001056358us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-01-012025-09-30 0001056358us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-09-30 0001056358us-gaap:AccumulatedTranslationAdjustmentMember2025-09-30 0001056358us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-09-30 00010563582023-03-10 utr:sqft 0001056358us-gaap:FairValueMeasurementsRecurringMember2025-09-30 0001056358us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-09-30 0001056358us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-09-30 0001056358us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-09-30 0001056358us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-31 0001056358us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-31 0001056358us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-31 0001056358us-gaap:FairValueMeasurementsRecurringMember2024-12-31 0001056358us-gaap:CarryingReportedAmountFairValueDisclosureMember2025-09-30 0001056358us-gaap:EstimateOfFairValueFairValueDisclosureMember2025-09-30 0001056358us-gaap:CarryingReportedAmountFairValueDisclosureMember2024-12-31 0001056358us-gaap:EstimateOfFairValueFairValueDisclosureMember2024-12-31 0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembersrt:AmericasMember2025-07-012025-09-30 0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembersrt:AmericasMember2024-07-012024-09-30 0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembersrt:AmericasMember2025-01-012025-09-30 0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembersrt:AmericasMember2024-01-012024-09-30 0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembersrt:AsiaPacificMember2025-07-012025-09-30 0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembersrt:AsiaPacificMember2024-07-012024-09-30 0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembersrt:AsiaPacificMember2025-01-012025-09-30 0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembersrt:AsiaPacificMember2024-01-012024-09-30 0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:EMEAMember2025-07-012025-09-30 0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:EMEAMember2024-07-012024-09-30 0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:EMEAMember2025-01-012025-09-30 0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:EMEAMember2024-01-012024-09-30 0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2025-07-012025-09-30 0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2024-07-012024-09-30 0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2025-01-012025-09-30 0001056358us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2024-01-012024-09-30 0001056358us-gaap:ProductMember2025-07-012025-09-30 0001056358us-gaap:ProductMember2024-07-012024-09-30 0001056358us-gaap:ProductMember2025-01-012025-09-30 0001056358us-gaap:ProductMember2024-01-012024-09-30 0001056358mtex:AssociateServiceFeesMember2025-07-012025-09-30 0001056358mtex:AssociateServiceFeesMember2024-07-012024-09-30 0001056358mtex:AssociateServiceFeesMember2025-01-012025-09-30 0001056358mtex:AssociateServiceFeesMember2024-01-012024-09-30 0001056358us-gaap:ProductAndServiceOtherMember2025-07-012025-09-30 0001056358us-gaap:ProductAndServiceOtherMember2024-07-012024-09-30 0001056358us-gaap:ProductAndServiceOtherMember2025-01-012025-09-30 0001056358us-gaap:ProductAndServiceOtherMember2024-01-012024-09-30 0001056358srt:AmericasMember2025-09-30 0001056358srt:AmericasMember2024-12-31 0001056358srt:AsiaPacificMember2025-09-30 0001056358srt:AsiaPacificMember2024-12-31 0001056358us-gaap:EMEAMember2025-09-30 0001056358us-gaap:EMEAMember2024-12-31 0001056358us-gaap:OperatingSegmentsMember2025-07-012025-09-30 0001056358us-gaap:OperatingSegmentsMember2024-07-012024-09-30 0001056358us-gaap:OperatingSegmentsMember2025-01-012025-09-30 0001056358us-gaap:OperatingSegmentsMember2024-01-012024-09-30 0001056358us-gaap:MaterialReconcilingItemsMember2025-07-012025-09-30 0001056358us-gaap:MaterialReconcilingItemsMember2024-07-012024-09-30 0001056358us-gaap:MaterialReconcilingItemsMember2025-01-012025-09-30 0001056358us-gaap:MaterialReconcilingItemsMember2024-01-012024-09-30 0001056358us-gaap:RestrictedStockUnitsRSUMember2025-07-012025-09-30 0001056358us-gaap:EmployeeStockOptionMember2025-07-012025-09-30 0001056358us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-30 0001056358us-gaap:EmployeeStockOptionMember2024-01-012024-09-30
     

     

    Table of Contents



    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     


     

    FORM 10-Q

    (Mark One)

     

    ☒         QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the quarterly period ended: September 30, 2025

     

    OR

     

    ☐         TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the transition period from ___________ to ___________.

     

    Commission File No. 000-24657

     

    MANNATECH, INCORPORATED

     

    (Exact Name of Registrant as Specified in its Charter)

     

    Texas

    75-2508900

    (State or other Jurisdiction of Incorporation or Organization)

    (I.R.S. Employer Identification No.)

    1410 Lakeside Parkway, Suite 200,

     

    Flower Mound, Texas

    75028

    (Address of Principal Executive Offices)

    (Zip Code)

     

    Registrant’s Telephone Number, including Area Code: (972) 471-7400

    Securities registered pursuant to Section 12(b) of the Act:

     

     Title of each class

     Trading Symbol(s)

     Name of each exchange on which registered

     Common Stock,  par value $0.0001 per share

     MTEX

     The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

     

    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “accelerated filer”, “large accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     Large accelerated filer

     ☐

    Accelerated filer

     ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

    Emerging Growth Company

    ☐

     

    If an emerging growth company, indicated by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

    Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

    Yes ☐ No ☒

     

    As of November 4, 2025, the number of shares outstanding of the registrant’s sole class of common stock, par value $0.0001 per share, was 1,900,930.

     

     

    Table of Contents

        

     

    MANNATECH, INCORPORATED

    TABLE OF CONTENTS

     

    Special Note Regarding Forward-Looking Statements

    1

    Part I – FINANCIAL INFORMATION

     

    Item 1. Financial Statements

    2

    Condensed Consolidated Balance Sheets (unaudited)

    2

    Condensed Consolidated Statements of Operations (unaudited)

    3

    Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited)

    4

    Condensed Consolidated Statements of Shareholders’ Equity (unaudited)

    5

    Condensed Consolidated Statements of Cash Flows (unaudited)

    6

    Notes to Condensed Consolidated Financial Statements (unaudited)

    8

       

    Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

    23

    Company Overview

    23

    Results of Operations

    24

    Liquidity and Capital Resources

    30

    Significant Accounting Policies and Critical Estimates

    32

       

    Item 3. Quantitative and Qualitative Disclosures About Market Risk

    34

       

    Item 4. Controls and Procedures

    34

       

    Part II – OTHER INFORMATION

     

    Item 1. Legal Proceedings

    35

       

    Item 1A. Risk Factors

    35

       

    Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

    35

       

    Item 3. Defaults Upon Senior Securities

    35

       

    Item 4. Mine Safety Disclosures

    35

       

    Item 5. Other Information

    35

       

    Item 6. Exhibits

    36

       

    Signatures

    37

     

     

    Table of Contents

        

     

    Special Note Regarding Forward-Looking Statements

     

    Certain disclosures and analyses in this Form 10-Q, including information incorporated by reference, may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995 that are subject to various risks and uncertainties. Opinions, forecasts, projections, guidance, or other statements other than statements of historical fact are considered forward-looking statements and reflect only current views about future events and financial performance. Some of these forward-looking statements include statements regarding:

     

     

    •

    management’s plans and objectives for future operations;

     

    •

    existing cash flows being adequate to fund future operational needs;

     

    •

    future plans related to budgets, future capital requirements, market share growth, and anticipated capital projects and obligations;

     

    •

    the realization of net deferred tax assets;

     

    •

    the ability to curtail operating expenditures;

     

    •

    global statutory tax rates remaining unchanged;

     

    •

    the impact of future market changes due to exposure to foreign currency translations;

     

    •

    the possibility of certain policies, procedures, and internal processes minimizing exposure to market risk;

     

    •

    the impact of new accounting pronouncements on financial condition, results of operations, or cash flows;

     

    •

    the outcome of new or existing litigation matters;

     

    •

    the outcome of new or existing regulatory inquiries or investigations;

     

    •

    other assumptions described in this report underlying such forward-looking statements.

     

    Although we believe that the expectations included in these forward-looking statements are reasonable, these forward-looking statements are subject to certain events, risks, assumptions, and uncertainties, including those discussed below, the “Risk Factors” section in Part I, Item 1A of our Form 10-K for the year ended December 31, 2024, and elsewhere in this Form 10-Q and the documents incorporated by reference herein. If one or more of these risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results and developments could materially differ from those expressed in or implied by such forward-looking statements. For example, any of the following factors could cause actual results to vary materially from our projections:

     

     

    •

    overall growth or lack of growth in the nutritional supplements industry;

     

    •

    plans for expected future product development;

     

    •

    changes in manufacturing costs;

     

    •

    shifts in the mix of packs and products;

     

    •

    the future impact of any changes to global associate career and compensation plans or incentives or the regulations governing such plans and incentives;

     

    •

    the ability to attract and retain independent associates and preferred customers;

     

    •

    new regulatory changes that may affect operations, products or compensation plans and incentives;

     

    •

    ability of our outside suppliers and manufacturers to supply products in sufficient quantities and comply with our product safety and quality standards or applicable law;

     

    •

    the competitive nature of our business with respect to products and pricing;

     

    •

    publicity related to our products or network marketing; and

     

    •

    the political, social and economic climate of the countries in which we operate; and

     

    •

    changes in trade policy in the United States and other countries, including the imposition of tariffs and the resulting consequences, may adversely impact our business, results of operations and financial condition.

     

    Forward-looking statements generally can be identified by use of phrases or terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “approximates,” “predicts,” “projects,” “hopes,” “potential,” and “continues” or other similar words or the negative of such terms and other comparable terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals, or targets contained herein are also considered forward-looking statements. Readers are cautioned when considering these forward-looking statements to keep in mind these risks, assumptions, and uncertainties and any other cautionary statements in this report, as all of the forward-looking statements contained herein speak only as of the date of this report.

     

    Unless stated otherwise, all financial information throughout this report and in the Condensed Consolidated Financial Statements and related Notes include Mannatech, Incorporated and all of its subsidiaries on a consolidated basis and may be referred to herein as “Mannatech,” “the Company,” “its,” “we,” “us,” “our,” or “their.”

     

    Our products are not intended to diagnose, cure, treat, or prevent any disease, and any statements about our products contained in this report have not been evaluated by the Food and Drug Administration, also referred to herein as the “FDA.”

     

     

    1

    Table of Contents
     

     

    PART I – FINANCIAL INFORMATION

     

    Item 1. Financial Statements

    MANNATECH, INCORPORATED AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS – (UNAUDITED)

    (in thousands, except share and per share amounts)

     

      

    September 30, 2025

      

    December 31, 2024

     

    ASSETS

            

    Cash and cash equivalents

     $7,141  $11,396 

    Restricted cash

      550   550 

    Accounts receivable, net of allowance of $783 and $935

      38   19 

    Income tax receivable

      732   737 

    Inventories, net

      11,128   10,405 

    Prepaid expenses and other current assets

      1,587   1,755 

    Deferred commissions

      909   1,259 

    Total current assets

      22,085   26,121 

    Property and equipment, net

      3,232   2,858 

    Operating lease right-of-use assets

      3,753   2,094 

    Other assets

      2,828   2,644 

    Deferred tax assets, net

      1,783   1,770 

    Long-term restricted cash

      239   569 

    Total assets

     $33,920  $36,056 

    LIABILITIES AND SHAREHOLDERS’ EQUITY

            

    Commissions and incentives payable

     $6,407  $8,642 

    Accrued expenses

      3,281   3,832 

    Deferred revenue

      2,290   3,027 

    Accounts payable

      4,005   2,070 

    Current portion of operating lease liabilities

      1,745   1,178 

    Taxes payable

      1,487   1,788 

    Current notes payable

      —   84 

    Current portion of finance lease liabilities

      288   275 

    Total current liabilities

      19,503   20,896 

    Long-term notes payable

      2,900   2,900 

    Operating lease liabilities, excluding current portion

      2,702   1,576 

    Other long-term liabilities

      1,402   1,390 

    Finance lease liabilities, excluding current portion

      463   680 

    Total liabilities

      26,970   27,442 
             

    Commitments and contingencies

              
             

    Shareholders’ equity:

            

    Preferred stock, $0.01 par value, 1,000,000 shares authorized, no shares issued or outstanding

      —   — 

    Common stock, $0.0001 par value, 99,000,000 shares authorized, 2,742,857 shares issued and 1,900,930 shares outstanding as of September 30, 2025 and 2,742,857 shares issued and 1,884,814 shares outstanding as of December 31, 2024

      —   — 

    Additional paid-in capital

      33,000   33,027 

    (Accumulated deficit) retained earnings

      (2,729)  1,189 

    Accumulated other comprehensive loss

      (3,759)  (5,666)

    Treasury stock, at average cost, 841,927 shares as of September 30, 2025 and 858,043 shares as of December 31, 2024

      (19,562)  (19,936)

    Total shareholders’ equity

      6,950   8,614 

    Total liabilities and shareholders’ equity

     $33,920  $36,056 

    See accompanying notes to unaudited condensed consolidated financial statements.

    2

    Table of Contents
     

     

    MANNATECH, INCORPORATED AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS – (UNAUDITED)

    (in thousands, except per share information)

     

       

    Three Months Ended

       

    Nine Months Ended

     
       

    September 30,

       

    September 30,

     
       

    2025

       

    2024

       

    2025

       

    2024

     

    Net sales

      $ 29,161     $ 31,725     $ 81,403     $ 88,858  

    Cost of sales

        6,890       8,105       20,495       20,763  

    Gross profit

        22,271       23,620       60,908       68,095  

    Operating expenses:

                                   

    Commissions and incentives

        11,192       12,893       31,312       36,237  

    Selling and administrative expenses

        9,072       9,840       29,865       31,293  

    Total operating expenses

        20,264       22,733       61,177       67,530  

    Income (loss) from operations

        2,007       887       (269 )     565  

    Interest expense, net

        (104 )     (109 )     (279 )     (196 )

    Other income (expense), net

        611       (1,495 )     (2,551 )     495  

    Income (loss) before income taxes

        2,514       (717 )     (3,099 )     864  

    Income tax (expense) benefit

        (590 )     389       (819 )     (636 )

    Net income (loss)

      $ 1,924     $ (328 )   $ (3,918 )   $ 228  

    Income (loss) per common share:

                                   

    Basic

      $ 1.01     $ (0.17 )   $ (2.06 )   $ 0.12  

    Diluted

      $ 1.01     $ (0.17 )   $ (2.06 )   $ 0.12  

    Weighted-average common shares outstanding:

                                   

    Basic

        1,901       1,885       1,901       1,885  

    Diluted

        1,901       1,885       1,901       1,885  

    See accompanying notes to unaudited condensed consolidated financial statements.

    3

    Table of Contents
     

     

    MANNATECH, INCORPORATED AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) – (UNAUDITED)

    (in thousands)

     

       

    Three Months Ended

       

    Nine Months Ended

     
       

    September 30,

       

    September 30,

     
       

    2025

       

    2024

       

    2025

       

    2024

     

    Net income (loss)

      $ 1,924     $ (328 )   $ (3,918 )   $ 228  

    Foreign currency translations

        (864 )     2,105       1,907       (982 )

    Comprehensive income (loss)

      $ 1,060     $ 1,777     $ (2,011 )   $ (754 )

     

    See accompanying notes to unaudited condensed consolidated financial statements.

     

    4

    Table of Contents
     

     

    MANNATECH, INCORPORATED AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY – (UNAUDITED)

    (amounts in thousands, except share data)

     

      

    Common Stock, $0.0001 par value

                         
                  

    (Accumulated

      

    Accumulated

             
              

    Additional

      

    deficit)

      

    other

          

    Total

     
      

    Number

          

    paid-in

      

    retained

      

    comprehensive

      

    Treasury

      

    shareholders’

     
      

    of Shares

      

    Amount

      

    capital

      

    earnings

      

    loss

      

    stock

      

    equity

     

    Balance at January 1, 2025

      1,884,814  $—  $33,027  $1,189  $(5,666) $(19,936) $8,614 

    Net loss

      —   —   —   (1,530)  —   —   (1,530)

    Charge related to stock-based compensation

      —   —   23   —   —   —   23 

    Issuance of unrestricted shares

      16,116   —   (134)  —   —   374   240 

    Foreign currency translations

      —   —   —   —   238   —   238 

    Balance at March 31, 2025

      1,900,930  $—  $32,916  $(341) $(5,428) $(19,562) $7,585 
                                 

    Net loss

      —   —   —   (4,312)  —   —   (4,312)

    Charge related to stock-based compensation

      —   —   158   —   —   —   158 

    Foreign currency translations

      —   —   —   —   2,533   —   2,533 

    Balance at June 30, 2025

      1,900,930  $—  $33,074  $(4,653) $(2,895) $(19,562) $5,964 
                                 

    Net income

      —   —   —   1,924   —   —   1,924 

    Charge related to stock-based compensation

      —   —   (74)  —   —   —   (74)

    Foreign currency translations

      —   —   —   —   (864)  —   (864)

    Balance at September 30, 2025

      1,900,930  $—  $33,000  $(2,729) $(3,759) $(19,562) $6,950 

     

     

      

    Common Stock, $0.0001 par value

                         
                      

    Accumulated

             
              

    Additional

          

    other

          

    Total

     
      

    Number

          

    paid-in

      

    Accumulated

      

    comprehensive

      

    Treasury

      

    shareholders’

     
      

    of Shares

      

    Amount

      

    capital

      

    deficit

      

    loss

      

    stock

      

    equity

     

    Balance at January 1, 2024

      1,860,154  $—  $33,309  $(1,301) $(1,015) $(20,509) $10,484 

    Net income

      —   —   —   1,180   —   —   1,180 

    Charge related to stock-based compensation

      —   —   12   —   —   —   12 

    Issuance of unrestricted shares

      24,660   —   (373)  —   —   573   200 

    Foreign currency translations

      —   —   —   —   (1,431)  —   (1,431)

    Balance at March 31, 2024

      1,884,814  $—  $32,948  $(121) $(2,446) $(19,936) $10,445 
                                 

    Net loss

      —   —   —   (624)  —   —   (624)

    Charge related to stock-based compensation

      —   —   34   —   —   —   34 

    Foreign currency translations

      —   —   —   —   (1,656)  —   (1,656)

    Balance at June 30, 2024

      1,884,814  $—  $32,982  $(745) $(4,102) $(19,936) $8,199 
                                 

    Net loss

      —   —   —   (328)  —   —   (328)

    Charge related to stock-based compensation

      —   —   23   —   —   —   23 

    Foreign currency translations

      —   —   —   —   2,105   —   2,105 

    Balance at September 30, 2024

      1,884,814  $—  $33,005  $(1,073) $(1,997) $(19,936) $9,999 

     

    See accompanying notes to unaudited condensed consolidated financial statements.

     

    5

    Table of Contents
     

     

    MANNATECH, INCORPORATED AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS – (UNAUDITED)

    (in thousands)

     

       

    Nine Months Ended

     
       

    September 30,

     
       

    2025

       

    2024

     

    CASH FLOWS FROM OPERATING ACTIVITIES:

                   

    Net (loss) income

      $ (3,918 )   $ 228  

    Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:

                   

    Depreciation and amortization

        832       1,174  

    Non-cash operating lease expense

        1,293       1,228  

    Provision for inventory losses

        82       661  

    Provision for allowance for credit losses

        (18 )     (319 )

    Loss on retirement of property and equipment

        —       253  

    Gain on disposal of subsidiary entity

        —       (226 )

    Unrealized loss (gain) from foreign exchange

        2,280       (146 )

    Charge related to stock-based compensation

        347       269  

    Deferred income taxes

        (13 )     (302 )

    Changes in operating assets and liabilities:

                   

    Accounts receivable

        20       388  

    Income tax receivable

        4       51  

    Inventories

        (504 )     2,214  

    Prepaid expenses and other current assets

        1,384       1,769  

    Deferred commissions

        356       906  

    Other assets

        (361 )     (9 )

    Accounts payable

        1,892       (430 )

    Accrued expenses

        (2,764 )     (827 )

    Other long-term liabilities

        12       (2,503 )

    Taxes payable

        (400 )     (159 )

    Commissions and incentives payable

        (2,447 )     28  

    Deferred revenue

        (751 )     (1,768 )

    Net cash (used in) provided by operating activities

        (2,674 )     2,480  

    CASH FLOWS FROM INVESTING ACTIVITIES:

                   

    Acquisition of property and equipment

        (1,179 )     (403 )

    Cash used in investing activities

        (1,179 )     (403 )

    CASH FLOWS FROM FINANCING ACTIVITIES:

                   

    Proceeds from notes payable

        —       3,600  

    Repayment of note payable

        (84 )     —  

    Repayment of finance lease obligations and other long-term liabilities

        (235 )     (734 )

    Net cash (used in) provided by financing activities

        (319 )     2,866  

    Effect of currency exchange rate changes on cash and cash equivalents

        (413 )     (606 )

    Net (decrease) increase in cash, cash equivalents, and restricted cash

        (4,585 )     4,337  

    Cash, cash equivalents, and restricted cash at the beginning of the period

        12,515       9,387  

    Cash, cash equivalents, and restricted cash at the end of the period

      $ 7,930     $ 13,724  

     

    See accompanying notes to unaudited condensed consolidated financial statements.

     

    6

    Table of Contents

     

       

    Nine Months Ended

     
       

    September 30,

     
       

    2025

       

    2024

     

    SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

                   

    Income taxes paid

      $ 783     $ 812  

    Interest paid on finance leases and other financing arrangements

      $ 388     $ 323  
                     

    NON-CASH INVESTING AND FINANCING ACTIVITIES:

                   

    Assets acquired through other financing arrangements

      $ —     $ 446  

    Operating lease right-of-use assets acquired in exchange for new operating lease liabilities

      $ 2,638     $ 359  

     

    See accompanying notes to unaudited condensed consolidated financial statements.

     

     
    7

    Table of Contents
    MANNATECH, INCORPORATED AND SUBSIDIARIES
    NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

     

     

    NOTE 1: ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

     

    Mannatech, Incorporated (together with its subsidiaries, the “Company”), located in Flower Mound, Texas, was incorporated in the state of Texas on November 4, 1993 and is listed on the Nasdaq Global Select Market under the symbol “MTEX.” The Company develops, markets, and sells high-quality, proprietary nutritional supplements, skin care and anti-aging products, and weight-management products. We currently sell our products into three regions: (i) the Americas (the United States, Canada and Mexico); (ii) EMEA (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden and the United Kingdom); and (iii) Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Thailand, Hong Kong, Taiwan and China).

     

    The Company sells its products principally through network marketing distribution channels via its active associates (“independent associate” or “associates” or “distributors”) and its “preferred customers,” Active business building associates and preferred customers purchase the Company’s products at published wholesale prices. The Company cannot distinguish products sold for personal use from other sales, when sold to associates, because it is not involved with the products after delivery, other than usual and customary product warranties and returns. Only associates are eligible to earn commissions and incentives. We also ship our products to customers in the following countries: Belgium, France, Greece, Italy, Luxembourg, and Poland. The Company operates a non-direct selling business in mainland China. Our subsidiary in China, Meitai Daily Necessity & Health Products Co., Ltd. (“Meitai”), is operating as a traditional retailer under a cross-border e-commerce model in China. Meitai cannot legally conduct a direct selling business in China unless it acquires a direct selling license in China.

     

    The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with instructions for Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, the Company’s condensed consolidated financial statements and footnotes contained herein do not include all of the information and footnotes required by GAAP to be considered “complete financial statements”. However, in the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements and footnotes contain all adjustments, including normal recurring adjustments, considered necessary for a fair presentation of the Company’s consolidated financial information as of, and for, the periods presented. The Company cautions that its consolidated results of operations for an interim period are not necessarily indicative of its consolidated results of operations to be expected for its fiscal year. The December 31, 2024 consolidated balance sheet was included in the audited consolidated financial statements in the Company’s annual report on Form 10-K for the year ended December 31, 2024 and filed with the United States Securities and Exchange Commission (the “SEC”) on March 25, 2025 (the “2024 Annual Report”), which includes all disclosures required by GAAP. Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company included in the 2024 Annual Report.

     

    Principles of Consolidation

     

    The condensed consolidated financial statements and footnotes include the accounts of Mannatech and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

     

    Use of Estimates

     

    The preparation of the Company’s condensed consolidated financial statements in accordance with GAAP requires the use of estimates that affect the reported value of assets, liabilities, revenues and expenses. These estimates are based on historical experience and various other factors. The Company continually evaluates the information used to make these estimates as the business and economic environment changes. Historically, actual results have not varied materially from the Company’s estimates and the Company does not currently anticipate a significant change in its assumptions related to these estimates. However, actual results may differ from these estimates under different assumptions or conditions.

     

    The use of estimates is pervasive throughout the condensed consolidated financial statements, but the accounting policies and estimates considered the most significant are described in this note to the condensed consolidated financial statements.

     

    Significant Accounting Policies

     

    Our significant accounting policies are described in the notes to our consolidated financial statements for the year ended December 31, 2024 included in our 2024 Annual Report. There have been no significant changes in our accounting policies or the application thereof during the period ended  September 30, 2025.

     

    8

    Table of Contents
    MANNATECH, INCORPORATED AND SUBSIDIARIES
    NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
     

    Cash and Cash Equivalents

     

    The Company considers all highly liquid investments with original maturities of three months or less at the date of acquisition to be cash equivalents. Cash and cash equivalents was $7.1 million at September 30, 2025 and $11.4 million at December 31, 2024. The Company includes in its cash and cash equivalents credit card receivables due from its credit card processor, as the cash proceeds from credit card receivables are received within 24 to 72 hours. At September 30, 2025 and December 31, 2024, credit card receivables were $2.1 million and $1.6 million, respectively, and cash and cash equivalents held in bank accounts in foreign countries totaled $2.6 million and $5.1 million at September 30, 2025 and December 31, 2024, respectively. The Company invests cash in liquid instruments, such as money market funds and interest-bearing deposits. The Company holds cash in high quality financial institutions and does not believe it has an excessive exposure to credit concentration risk.

     

    Restricted Cash

     

    The Company is required to restrict cash for: (i) direct selling insurance premiums and credit card sales in the Republic of Korea; (ii) reserves related to credit card sales in the United States and Canada; and (iii) the Australia building lease collateral. At September 30, 2025 and December 31, 2024, our total restricted cash was $0.8 million and $1.1 million, respectively.

     

    The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Company's condensed consolidated balance sheets to the total amount presented in the condensed consolidated statement of cash flows (in thousands):

     

      

    September 30, 2025

      

    December 31, 2024

     

    Cash and cash equivalents

     $7,141  $11,396 

    Current restricted cash

      550   550 

    Long-term restricted cash

      239   569 

    Cash, cash equivalents, and restricted cash

     $7,930  $12,515 

     

    Accounts Receivable, net

     

    Accounts receivable are carried at their estimated collectible amounts. Receivables are created upon shipment of an order if the credit card payment is rejected or does not match the order total. As of September 30, 2025 and December 31, 2024, receivables consisted primarily of amounts due from preferred customers and associates.

     

    The Company's accounts receivable balances, net, are presented below (in thousands):

     

      

    September 30, 2025

      

    December 31, 2024

     

    Accounts receivable, net

     $38  $19 

     

    In accordance with Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASC 326"), the Company assesses collectability by reviewing accounts receivable on a collective basis where similar characteristics exist and on an individual basis when the Company identifies specific customers with known disputes or collectability issues. Expected loss estimates are determined utilizing an aging schedule. In determining the amount of the allowance for credit losses, the Company considers historical collectability based on past due status and makes judgments about the creditworthiness of customers based on ongoing credit evaluations. The Company also considers customer-specific information, current market conditions and reasonable and supportable forecasts of future economic conditions to inform adjustments to historical loss data.

     

    At September 30, 2025 and September 30, 2024, the Company held an allowance for credit losses of $0.8 million and $0.9 million, respectively.

     

      

    September 30, 2025

      

    September 30, 2024

     

    Allowance for credit losses at beginning of period

     $935  $1,278 

    Provision in current period

      (18)  (319)

    Accounts charged off against the allowance

      (134)  (27)

    Allowance for credit losses at end of period

     $783  $932 

     

    9

    Table of Contents
    MANNATECH, INCORPORATED AND SUBSIDIARIES
    NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
     

    Inventories

     

    Inventories consist of raw materials, finished goods, and promotional materials that are stated at the lower of cost (using standard costs that approximate average costs) or net realizable value. The Company periodically reviews inventories for obsolescence and any inventories identified as obsolete are reserved or written off.

     

    Other Assets

     

    Other Assets consisted of the following (in thousands):

     

      

    September 30, 2025

      

    December 31, 2024

     

    Investment in Korea Mutual Aid Cooperative & Consumer

     $1,318  $1,255 

    Deposits for building leases

      1,273   1,152 

    Manapol Trademark

      237   237 
      $2,828  $2,644 

     

    The Company accounts for its investment in Korea Mutual Aid Cooperative & Consumer at its initial investment amount, in accordance with ASC 321, Investments - Equity Securities (“ASC 321”). This guidance offers an alternative to the requirement of carrying equity interests at fair value as per ASC 820, Fair Value Measurement. The measurement alternative is applicable to certain equity interests without readily determinable fair values that fall within the scope of ASC 321 and are otherwise required to be measured at fair value. The application of this measurement alternative is optional and is applied upon the acquisition of an equity interest.

     

    Accrued Expenses

     

    Accrued expenses consisted of the following (in thousands):

     

      

    September 30, 2025

      

    December 31, 2024

     

    Accrued compensation

     $1,461  $1,320 

    Accrued legal and accounting fees

      649   823 

    Customer deposits and sales returns

      172   480 

    Other accrued operating expenses

      359   530 

    Accrued shipping and handling costs

      204   306 

    Accrued sales and other taxes

      156   157 

    Accrued travel expenses related to corporate events

      141   127 

    Accrued inventory purchases

      123   45 

    Accrued royalties

      16   39 

    Accrued rent expense

      —   5 
      $3,281  $3,832 

     

    Other Long-Term Liabilities

     

    Other long-term liabilities consisted of the following (in thousands). See Note 9, Employee Benefit Plans, of the Company’s 2024 Annual Report for more information.

     

      

    September 30, 2025

      

    December 31, 2024

     

    Government required severance

     $843  $853 

    Accrued lease restoration costs

      343   326 

    Defined benefit plan obligation

      216   211 
      $1,402  $1,390 

     

    10

    Table of Contents
    MANNATECH, INCORPORATED AND SUBSIDIARIES
    NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
     

    Revenue Recognition

     

    The Company’s revenue is derived from sales of individual products and associate fees or, a combination, in certain geographic markets. Substantially all of the Company’s product sales are made at published wholesale prices to associates and preferred customers. The Company records revenue net of any sales taxes and records a reserve for expected sales returns based on its historical experience. The Company's shipping terms with customers are such that ownership transfers upon delivery to the freight carrier, satisfying the Company's performance obligation. The Company's remaining performance obligations related to associate fees were $0.1 million at both September 30, 2025 and December 31, 2024. These amounts are included in deferred revenue on the accompanying Condensed Consolidated Balance Sheets, respectively.

     

    Orders placed by associates or preferred customers constitute our contracts with customers. Product sales placed in the form of an automatic order contain two performance obligations: (a) the sale of the product and (b) the loyalty program. The Company's customer loyalty program conveys a material right to the customer to redeem loyalty points for the purchase of products. For these contracts, the Company accounts for each of these obligations separately as they are each distinct. The transaction price is allocated between the product sale and the loyalty program on a relative standalone selling price basis. Sales placed through a one-time order contain only the first performance obligation noted above — the delivery of the product. Payments are made immediately through credit card upon purchase of the products.

     

    The Company provides associates with access to a complimentary three-month package for the Success Tracker™ and Mannatech+ online business tools with the first payment of an associate fee. The first payment of an associate fee contains three performance obligations: (a) the associate fee, whereby the Company provides an associate with the right to earn commissions, bonuses and incentives for a year, (b) three months of complimentary access to utilize the Success Tracker™ online tool and (c) three months of complimentary access to utilize the Mannatech+ online business tool. The transaction price is allocated between the three performance obligations on a relative standalone selling price basis and revenue is recognized over the period that access to the tools is active. Associates do not have complimentary access to online business tools after the first contractual period.

     

    With regard to both of the aforementioned contracts, the Company determines the standalone selling prices by using observable inputs.

     

    Deferred Revenue

     

    The Company defers certain components of its revenue. Deferred revenue consisted of: (i) revenue from the loyalty program; (ii) prepaid registration fees from customers planning to attend a future corporate-sponsored event; and (iii) prepaid annual associate fees.

     

    The table below presents the changes to deferred revenue balances (in thousands).

     

      

    Three Months Ended

      

    Nine Months Ended

     
      

    September 30,

      

    September 30,

     
      

    2025

      

    2024

      

    2025

      

    2024

     

    Total deferred revenue at beginning of the period

     $2,046  $4,152  $3,027  $4,786 

    Amount recognized as revenue during the period that is included in beginning of the period

      (331)  (1,836)  (2,833)  (4,747)

    New deferrals at the end of the period, net

      575   702   2,096   2,979 

    Total deferred revenue at end of the period

     $2,290  $3,018  $2,290  $3,018 

     

    The Company’s customer loyalty program conveys a material right to the customer as it provides the promise to redeem loyalty points for the purchase of products, which is based on earning points through placing consecutive qualified orders. The Company factors in breakage rates, which is the percentage of the loyalty points that are expected to be forfeited or expire, for purposes of revenue recognition. Breakage rates are estimated based on historical data and can be reasonably and objectively determined.

     

    11

    Table of Contents
    MANNATECH, INCORPORATED AND SUBSIDIARIES
    NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
     

    The deferred revenue associated with the loyalty program at September 30, 2025 and September 30, 2024 was $2.2 million and $2.9 million, respectively.

     

      

    Three Months Ended

      

    Nine Months Ended

     
      

    September 30,

      

    September 30,

     

    Loyalty program (in thousands)

     

    2025

      

    2024

      

    2025

      

    2024

     

    Loyalty deferred revenue at beginning of the period

     $1,972  $2,861  $2,921  $3,242 

    Loyalty points forfeited or expired

      (1,189)  (757)  (2,277)  (2,167)

    Loyalty points used

      (1,904)  (2,227)  (5,946)  (6,745)

    Loyalty points vested

      3,004   1,624   7,185   7,171 

    Loyalty points unvested

      320   1,399   320   1,399 

    Loyalty deferred revenue at end of period

     $2,203  $2,900  $2,203  $2,900 

     

    Deferred Commissions

     

    The Company defers commissions on (i) the sales of products shipped but not received by customers by the end of the respective period (up to the change in shipping terms with the customers, which occurred during the quarter ended September 30,2024) and (ii) the loyalty program. Deferred commissions are incremental costs and are charged to expense when the related revenue is recognized.

     

    The table below illustrates the changes to deferred commission balances (in thousands).

     

      

    Three Months Ended

      

    Nine Months Ended

     
      

    September 30,

      

    September 30,

     
      

    2025

      

    2024

      

    2025

      

    2024

     

    Deferred commissions at beginning of the period

     $730  $1,910  $1,259  $2,130 

    Amount recognized as commissions expense

      (90)  (734)  (1,091)  (1,899)

    New commission deferrals at the end of the period

      269   48   741   993 

    Total deferred commissions at end of the period

     $909  $1,224  $909  $1,224 

     

    Sales Refunds and Allowances

     

    The Company utilizes the expected value method, as set forth by Accounting Standard Codification ("ASC") Topic 606 Revenue from Contracts with Customers ("ASC 606"), to estimate the sales returns and allowance liability by taking the weighted average of the sales return rates over a rolling six-month period. The Company allocates the total amount recorded within the sales return and allowance liability as a reduction of the overall transaction price for the Company’s product sales. The Company deems the sales refund and allowance liability to be variable consideration.

     

    Historically, sales returns have not materially changed through the years, as the majority of our customers who return their merchandise do so within the first 90 days after the original sale. Sales returns have historically averaged 0.5% or less of our gross sales.

     

    As of each of the periods shown below, our sales return reserve consisted of the following (in thousands):

     

      

    September 30, 2025

      

    September 30, 2024

     

    Sales reserve at beginning of period

     $56  $41 

    Provision in current period

      587   627 

    Returns charged off against the reserve

      (576)  (606)

    Sales reserve at end of period

     $67  $62 

     

    12

    Table of Contents
    MANNATECH, INCORPORATED AND SUBSIDIARIES
    NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
     

    Shipping and Handling Costs

     

    The Company records inbound freight as a component of inventory and cost of sales. The Company records freight and shipping fees collected from its customers as fulfillment costs. Freight and shipping fees are accounted for as activities to fulfill the promise to transfer the products to the customer, not as a separate performance obligation.

     

    Commissions and Incentives

     

    Associates earn commissions and incentives based on their direct and indirect commissionable net sales over each month of the fiscal year. The Company accrues commissions and incentives when earned by associates and pays commissions on product sales on a monthly basis.

     

    Comprehensive Loss and Accumulated Other Comprehensive Loss

     

    Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources and includes all changes in equity during a period except those resulting from investments by owners and distributions to owners. The Company’s comprehensive loss consists of the Company’s net loss, foreign currency translation adjustments from its Japan, Republic of Korea, Denmark, Norway, Sweden, Mexico, Taiwan and China operations, remeasurement of intercompany balances of a long-term-investment nature from its Mexico, Taiwan, and Cyprus operations, and changes in the pension obligation for its Japanese employees.

     

    Accounting Pronouncements Issued but Not Yet Effective

     

    Income Tax Reporting (ASU 2023-09) — Income Taxes (Topic 740): Improvements to Income Tax Disclosures(“ASU 2023-09”). In December 2023, the FASB issued accounting guidance to expand the annual disclosure requirements for income taxes, primarily related to the rate reconciliation and income taxes paid. This guidance was effective January 1, 2025, with early adoption permitted. This guidance can be applied prospectively or retrospectively. The Company is currently evaluating the disclosure impacts of ASU 2023-09 on its consolidated financial statements as well as the impacts to its financial reporting process and related internal controls.

     

    Income Statement Expenses (ASU 2024-03) — Income Statement (Subtopic 220-40) - Reporting Comprehensive Income - Expense Disaggregation Disclosures. In November 2024, the FASB issued accounting guidance which is intended to improve expense disclosures, primarily by requiring disclosure of disaggregated information about certain income statement expense line items on an annual and interim basis. The ASU does not change the expense captions an entity presents on the face of the income statement; rather, it requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. ASU 2024-03 becomes effective January 1, 2027. The Company is currently evaluating the disclosure impacts of ASU 2024-03 on its consolidated financial statements as well as the impacts to its financial reporting process and related internal controls.

     

    Credit Losses (ASU 2025-05) – Financial Instruments-Credit Losses (Topic 326) - Measurement of Credit Losses for Accounts Receivable and Contract Assets. In July 2025, the FASB issued accounting guidance which introduces a practical expedient for the application of the current expected credit loss (“CECL”) model to current accounts receivable and contract assets. This guidance is effective beginning in the first quarter of fiscal year 2027 on a prospective basis, with early adoption permitted. The Company is currently evaluating the impacts of ASU 2025-05 on its consolidated financial statements as well as the impacts to its financial reporting process and related internal controls.

     

    Intangibles—Goodwill and Other—Internal-Use Software (ASU 2025-06) (Subtopic 350-40) - Targeted Improvements to the Accounting for Internal-Use Software. In September 2025, the FASB issued ASU 2025-06, which provides targeted improvements to the accounting for internal-use software. The amendments are intended to modernize and simplify the guidance by aligning it more closely with the economic substance of software development activities. The amendments are effective for all entities for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual periods. Early adoption is permitted in any interim or annual reporting period for which financial statements have not yet been issued or made available for issuance. If early adoption is elected in an interim period, the entity must adopt the amendments as of the beginning of the annual reporting period that includes that interim period. The Company is currently evaluating the impact of the adoption of ASU 2025-06 on our consolidated financial statements and related disclosures.

     

    Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

      

     

    13

    Table of Contents
    MANNATECH, INCORPORATED AND SUBSIDIARIES
    NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

     

     

    NOTE 2: INVENTORIES

     

    Inventories consist of raw materials, finished goods, and promotional materials. The Company provides an allowance for any slow-moving or obsolete inventories. The allowance for slow-moving inventory obsolescence was $0.1 million and $0.6 million at September 30, 2025 and December 31, 2024, respectively.

     

    Inventories as of September 30, 2025 and December 31, 2024, consisted of the following (in thousands):

     

      

    September 30, 2025

      

    December 31, 2024

     

    Raw materials

     $3,417  $4,438 

    Finished goods and promotional materials

      7,711   5,967 

    Total

     $11,128  $10,405 

      

     

    NOTE 3: INCOME TAXES

     

    For the three and nine months ended September 30, 2025, the Company’s effective tax rate was 23.5% and (26.4)%, respectively. For the three and nine months ended September 30, 2024, the Company's effective tax rate was 54.3% and 73.6%, respectively. For the three and nine months ended September 30, 2025 and 2024, the Company's effective tax rate was determined based on the estimated annual effective income tax rate. The effective tax rate for the three and nine months ended September 30, 2025 and September 30, 2024, was different from the federal statutory rate due to the mix of earnings across jurisdictions and the associated valuation allowances recorded on losses in certain jurisdictions.

        

     

    NOTE 4: NOTES PAYABLE

     

    Notes payable were $2.9 million and $3.0 million as of September 30, 2025 and December 31, 2024, respectively.

     

    The current portion was $0.0 million and $0.1 million at September 30, 2025 and December 31, 2024, respectively, as a result of insurance financing arrangements.

     

    The long-term portion of notes payable relates to three unsecured notes, described below. The long-term portion of notes payable was $2.9 million at each of September 30, 2025 and December 31, 2024.

     

    On April 23, 2024, the Company issued an unsecured note payable to Jade Capital in the amount of $2.5 million. The note bears interest at 16% per annum and requires quarterly interest payments beginning June 30, 2024. The note is due in full on September 30, 2026. The Company has the right to prepay all or a portion of the Promissory Note at any time without premium or penalty. Tyler Rameson is an independent member of Mannatech's Board of Directors and is the managing member of Jade Capital. As of September 30, 2025, there was no current portion, and the long-term portion of the balance was $2.0 million. On September 9, 2025, the Company entered into a loan extension agreement with Jade Capital, extending the maturity date of the note from September 30, 2026, to March 31, 2027.  All other terms of the note remained unchanged.

     

    On April 23, 2024, the Company issued an unsecured note payable to J. Stanley Fredrick in the amount of $1.0 million. The note bears interest at 16% per annum and requires quarterly interest payments beginning June 30, 2024. The note is due in full on September 30, 2026. The Company has the right to prepay all or a portion of the Promissory Note at any time without premium or penalty. Mr. Fredrick is the Chairman of Mannatech's Board of Directors. As of September 30, 2025, there was no current portion, and the long-term portion of the balance was $0.8 million. On September 9, 2025, the Company entered into a loan extension agreement with J. Stanley Fredrick, extending the maturity date of the note from September 30, 2026, to March 31, 2027.  All other terms of the note remained unchanged.

     

    On April 23, 2024, the Company issued an unsecured note payable to Kevin Robbins in the amount of $0.1 million. The note bears interest at 16% per annum and requires quarterly interest payments beginning June 30, 2024. The note is due in full on September 30, 2026. The Company has the right to prepay all or a portion of the Promissory Note at any time without premium or penalty. Mr. Robbins is a member of Mannatech's Board of Directors. As of September 30, 2025, there was no current portion, and the long-term portion of the balance was $0.1 million. On September 9, 2025, the Company entered into a loan extension agreement with Kevin Robbins, extending the maturity date of the note from September 30, 2026, to March 31, 2027.  All other terms of the note remained unchanged.

     

    As of September 30, 2025, the Company's future principal payments on notes payable were as follows (in thousands):

     

    Principal Payments

     

    Remaining 2025

      

    2026

      

    2027

      

    Total

     

    Jade Capital Note

     $—  $—  $2,014  $2,014 

    J.S. Fredrick Note

      —   —   806   806 

    K. Robbins Note

      —   —   80   80 

    Total

     $—  $—  $2,900  $2,900 

     

    14

    Table of Contents
    MANNATECH, INCORPORATED AND SUBSIDIARIES
    NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
        
     

    NOTE 5: STOCK-BASED COMPENSATION

     

    Stock Option Plan

     

    The Company currently has one active stock-based compensation plan, the Mannatech, Incorporated 2017 Stock Incentive Plan, which was adopted by the Company’s Board of Directors (the "Board") on April 17, 2017 and was approved by its shareholders on June 8, 2017, and subsequently amended by the Board in February 2019, which amendment was approved by the Company's shareholders on June 11, 2019 (as amended, the "2017 Plan"). The Board has reserved a maximum of 370,000 shares of our common stock that may be issued under the 2017 Plan (subject to adjustments for stock splits, stock dividends or other changes in corporate capitalization). As of September 30, 2025, the Company had a total of 49,875 shares available for grant under the 2017 Plan, which expires on April 16, 2027.

     

    The 2017 Plan provides for grants of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock and performance stock units to our employees, board members, and consultants. However, only employees of the Company and its corporate subsidiaries are eligible to receive incentive stock options. The exercise price per share for all stock options will be no less than the market value of a share of common stock on the date of grant. Any incentive stock option granted to an employee owning more than 10% of our common stock will have an exercise price of no less than 110% of our common stock’s market value on the grant date.

     

    The majority of stock options vest over two or three years, and generally are granted with a term of ten years, or five years in the case of an incentive option granted to an employee who owns more than 10% of our common stock.

     

    The Company is required to measure and recognize compensation expense related to any outstanding and unvested stock options in its consolidated financial statements using a fair-value based option-pricing model. The Company records stock-based compensation expense related to granting stock options in selling and administrative expenses. The fair value of the stock option award is calculated using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires us to apply judgment and use subjective assumptions about expected dividend yields, risk-free interest rates, price volatility related to the underlying shares, and the expected stock option life, including forfeitures.

     

    During the nine months ended September 30, 2025 and 2024, the Company granted 68,000 and 14,500 stock options, respectively. The weighted average fair value of stock options granted during the nine months ended September 30, 2025 and 2024 was approximately $ 6.06 and $ 4.47, respectively.

     

    The following assumptions were used to calculate the fair value of stock options granted:

     

      

    June 2025 Grants

     

    Estimated fair value per share of options granted:

     $6.08 

    Assumptions:

        

    Annualized dividend yield

      —%

    Risk-free rate of return

      3.9% - 4.0% 

    Common stock price volatility

      68.8%

    Expected average life of stock options (in years)

      4.5 

     

    The computation of the expected volatility assumption used in the Black-Scholes calculations for new grants is based on historical volatility of the Company’s stock. The expected life assumptions are based on the Company’s historical employee exercise and forfeiture behavior.

     

    Stock Grants

     

    On March 11, 2024, the Company issued a grant of 8,187 restricted stock units (“RSUs”) of our common stock to our Chief Executive Officer. Under the terms of the stock grant, the grant is available for 18 months and will not vest until Mannatech's stock price averages $15.00 per share (i.e., the volume weighted price) for 60 consecutive days.  As of the end of the performance period, the stock price condition was not met. Accordingly, the RSUs did not vest, and the grant lapsed with no shares issued.

     

    The Company is required to measure and recognize compensation expense related to the grant in its consolidated financial statements using a fair-value based model. The Company has determined the fair value of the grant is $ 0.1 million. Accordingly, the Company has recognized compensation expense related to the grant of $6 thousand and $ 26 thousand for the three and nine months ended September 30, 2025, respectively.

     

    15

    Table of Contents
    MANNATECH, INCORPORATED AND SUBSIDIARIES
    NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
     

    The Company recognized compensation expense related to the fair values of options and RSUs as follows for the three and nine months ended September 30, (in thousands):

     

      

    Three Months Ended

      

    Nine Months Ended

     
      

    September 30,

      

    September 30,

     
      

    2025

      

    2024

      

    2025

      

    2024

     

    Total gross compensation expense

     $38  $23  $107  $36 

    Total tax benefit associated with compensation expense

      2   3   10   8 

    Total net compensation expense

     $36  $20  $97  $28 

     

    As of September 30, 2025, the Company expects to record compensation expense related to stock options and RSUs in the future as follows (in thousands):

     

      

    Three months ending

             
      

    December 31,

      

    Years ending December 31,

     
      

    2025

      

    2026

      

    2027

     

    Total gross unrecognized compensation expense

     $32  $—  $— 

     

    Equity-Based Compensation to Directors

     

    At the discretion of the Board, each director may receive a portion of their fees payable in stock grants in lieu of cash compensation. For the nine months ended September 30, 2025 and 2024, the Company issued a total of 16,116 and 24,660 shares of treasury stock to the members of the Board as a part of their compensation, respectively. The stock grants to the Board were vested upon grant and the Company recognized $0.2 million compensation expense for each of the nine months ending September 30, 2025 and 2024.

     

    16

    Table of Contents
    MANNATECH, INCORPORATED AND SUBSIDIARIES
    NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
        
     

    NOTE 6: SHAREHOLDERS’ EQUITY

     

    Treasury Stock

     

    There were no shares repurchased during each of the three and nine months ended September 30, 2025 and 2024.

     

    As of September 30, 2025 and December 31, 2024, the Company had 841,927 and 858,043 treasury shares, respectively.

     

    Accumulated Other Comprehensive Loss

     

    Accumulated other comprehensive loss displayed in the Condensed Consolidated Statement of Shareholders’ Equity represents the results of certain shareholders’ equity changes not reflected in the Condensed Consolidated Statements of Operations, such as foreign currency translation and certain pension and post-retirement benefit obligations.

     

    The after-tax components of accumulated other comprehensive loss are as follows (in thousands):

     

          

    Pension and

      

    Accumulated

     
      

    Foreign

      

    Postretirement

      

    Other

     
      

    Currency

      

    Benefit

      

    Comprehensive

     
      

    Translation

      

    Obligation

      

    Loss, Net

     

    Balance as of December 31, 2024

     $(6,080) $414  $(5,666)

    Current-period change (1)

      1,907   —   1,907 

    Balance as of September 30, 2025

     $(4,173) $414  $(3,759)

     

    (1) No material amounts were reclassified from accumulated other comprehensive loss.

     

    Dividends

     

    Holders of Common Stock are entitled to receive dividends at the same rate, when, as and if declared by our Board of Directors out of funds legally available therefore, subject to any statutory or contractual restrictions on the payment of dividends and to the rights of the holders of one or more outstanding series of our preferred stock. For each of the three and nine months ended September 30, 2025 and 2024, the Company did not pay any dividends.

        

     

    NOTE 7: LITIGATION

     

    Litigation in General

     

    As of September 30, 2025, the Company had no open or pending litigation and no legal reserve was deemed necessary. The Company has incurred several claims in the normal course of business. The Company believes such claims can be resolved without any material adverse effect on its consolidated financial position, results of operations, or cash flows.

     

    The Company maintains certain liability insurance; however, certain costs of defending lawsuits are not covered by or only partially covered by its insurance policies, including claims that are below insurance deductibles. Additionally, insurance carriers could refuse to cover certain claims, in whole or in part. The Company accrues costs to defend itself from litigation as they are incurred.

        

     

    NOTE 8: LEASES

     

    The Company has entered into contractual lease arrangements to rent office space and equipment from third-party lessors and accounts for leases in accordance with ASC Topic 842. See Note 5 to the consolidated financial statements in our 2024 Annual Report. Right of use assets represent the Company’s right to use an underlying asset over the lease term and lease liabilities represent the Company’s obligation to make future lease payments arising from the lease.

     

    Generally, the Company’s operating leases relate to office space used in Mannatech’s operations, including its headquarters in Flower Mound, Texas and office space in international locations in which the Company does business. As of September 30, 2025 and December 31, 2024, all of the Company’s finance leases pertain to certain equipment used in the business.

     

    On March 10, 2023, the Company entered into a five-year agreement to sublease 10,000 rentable square feet of the Company's leased office space in Flower Mound, Texas to a subtenant. There was no modification or impairment by entering into the sublease agreement because the Company was not released from its obligations under the head lease. Sublease income is presented as a component of net sales on the Company's Condensed Consolidated Statements of Operations. The Company has made a policy election in accordance with ASC 842-10-15-39A to exclude from consideration taxes that are assessed on and collected from the sublessee from consideration. For the three and nine months ended September 30, 2025, the Company had earned less than $0.1 million and $0.1 million income from the sublease, respectively. For the three and nine months ended September 30, 2024, the Company earned less than $0.1 million and $0.1 million income from the sublease, respectively.

     

    17

    Table of Contents
    MANNATECH, INCORPORATED AND SUBSIDIARIES
    NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
     

    As of September 30, 2025, the Company had net operating lease right-of-use assets of $3.8 million and net finance lease right-of-use assets of $0.8 million. At September 30, 2025, our operating lease liabilities were $4.4 million and our finance lease liabilities were $0.8 million.

     

    The weighted-average remaining lease term and discount rate related to the Company’s operating lease liabilities as of September 30, 2025 were 2.60 years and 4.54%, respectively. The weighted-average remaining lease term and discount rate related to the Company’s finance lease liabilities as of September 30, 2025 were 2.55 years and 6.45%, respectively. The Company uses the discount rates implicit in each lease, or an estimate of the Company’s incremental borrowing rate if the rate implicit in a lease cannot be readily determined.

     

    As of September 30, 2025 and December 31, 2024 our right-of-use assets and lease liabilities balances, net of accumulated amortization, were as follows (in thousands):

     

    Leases

     

    Classification

     

    September 30, 2025

      

    December 31, 2024

     

    Right-of-use assets

              

    Operating leases

     

    Operating lease right-of-use assets

     $3,753  $2,094 

    Finance leases

     

    Property and equipment, net

      767   961 

    Total right-of-use assets

       $4,520  $3,055 
               

    Current portion of lease liabilities

              

    Operating leases

     

    Current portion of operating leases

     $1,745  $1,178 

    Finance leases

     

    Current portion of finance leases

      288   275 

    Long-term portion of lease liabilities

              

    Operating leases

     

    Operating lease liabilities, excluding current portion

      2,702   1,576 

    Finance leases

     

    Finance leases, excluding current portion

      463   680 

    Total lease liabilities

       $5,198  $3,709 

     

    As of September 30, 2025, the Company’s future sublease income and minimum future lease payments on operating and finance leases were as follows (in thousands):

     

    Future Maturities of Leases

     

    Operating Leases

      

    Finance Leases

      

    Sublease Income

     

    Remaining 2025

     $517  $82  $(33)

    2026

      1,862   327   (132)

    2027

      1,571   315   (132)

    2028

      806   90   (55)

    Total minimum lease payments

      4,756   814   (352)

    Imputed interest

      (309)  (63)  — 

    Present value of minimum lease payments

     $4,447  $751  $(352)

     

    18

    Table of Contents
    MANNATECH, INCORPORATED AND SUBSIDIARIES
    NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
        
     

    NOTE 9: FAIR VALUE

     

    The Company utilizes fair value measurements to record fair value adjustments to certain financial assets and to determine fair value disclosures.

     

    Fair Value Measurements and Disclosure (Topic 820) of the FASB establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:

     

     

    •

    Level 1 – Quoted unadjusted prices for identical instruments in active markets.

     

     

    •

    Level 2 – Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-derived valuations in which all observable inputs and significant value drivers are observable in active markets.

     

     

    •

    Level 3 – Model-derived valuations in which one or more significant inputs or significant value drivers are unobservable, including assumptions developed by the Company.

     

    The primary objective of the Company’s investment activities is to preserve principal while maximizing yields without significantly increasing risk. The investment instruments held by the Company are money market funds and interest-bearing deposits for which quoted market prices are readily available. The Company considers these highly liquid investments to be cash equivalents. These investments are classified within Level 1 of the fair value hierarchy because they are valued based on quoted market prices in active markets. The Company does not have any material financial liabilities that were required to be measured at fair value on a recurring basis at September 30, 2025.

     

    As of September 30, 2025 and December 31, 2024, the carrying amount of the financial instruments such as cash and cash equivalents (excluding money market funds disclosed in the table below), restricted cash, long-term restricted cash and accounts payable approximate their fair value due to short-term nature and the market rates of interest of these instruments. As such, these instruments are classified as Level 1.

     

    The tables below present the recorded amount of financial assets measured at fair value (in thousands) on a recurring basis as of September 30, 2025 and December 31, 2024.

     

      

    September 30, 2025

     
      

    Level 1

      

    Level 2

      

    Level 3

      

    Total

     

    Assets

                    

    Money Market Funds – JPMorgan Chase, US

     $1,638  $—  $—  $1,638 

     

      

    December 31, 2024

     
      

    Level 1

      

    Level 2

      

    Level 3

      

    Total

     

    Assets

                    

    Money Market Funds – JPMorgan Chase, US

     $4,005  $—  $—  $4,005 

     

    The following table below present the carrying amount and estimated fair value of financial instruments as of September 30, 2025 and December 31, 2024, (in thousands) that are not measured at fair value:

     

      

    September 30, 2025

     
      

    Carrying Value

      

    Estimated Fair Value

     

    Long-term notes payable

     $2,900  $2,811 

     

      

    December 31, 2024

     
      

    Carrying Value

      

    Estimated Fair Value

     

    Long-term notes payable

     $2,900  $2,813 

     

    The fair value was estimated using a net present value measurement, which is based on unobservable inputs, and as such, is classified as Level 3.

     

    19

    Table of Contents
    MANNATECH, INCORPORATED AND SUBSIDIARIES
    NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
        
     

    NOTE 10: SEGMENT INFORMATION

     

    The Company operates as a direct seller in the nutritional supplement industry. The Company's sole reporting segment is one in which it sells proprietary nutritional supplements, skin care and anti-aging products, and weight-management and fitness products operating in twenty-five markets. The products are primarily sold through a network marketing distribution channel of approximately 119,000 active associates and preferred customer positions who we refer to as current associates and preferred customers. The Company's subsidiary in China, Meitai, is currently operating as a traditional retailer under a cross-border e-commerce model. Meitai cannot legally conduct a direct selling business in China unless it acquires a direct selling license in China. Each of our subsidiaries sells similar products and exhibits similar economic characteristics, such as selling prices, paying commissions and incentives, gross margins and operating characteristics.

     

    The Chief Operating Decision Maker (“CODM”) is the Company’s Chief Executive Officer. The CODM regularly reviews consolidated financial information and performance used to make decisions about the Company as a whole and without distinguishing or grouping of operations based on asset type, revenue, geographic location, tenant or other factors. Accordingly, for disclosure purposes, the Company has a single reportable segment, which is reported on the Company’s consolidated financial statements.

     

    The CODM evaluates performance and allocates resources based on net income as reported in the consolidated statements of operations. Total expenditures for long-lived assets are reported on the consolidated statements of cash flows.

     

    Measure of total assets is consistent with the amounts reported on the consolidated balance sheet. The CODM reviews consolidated net income to evaluate income generated from assets (return on assets) in deciding whether to reinvest profits to grow the property portfolio or deploy income into other aspects of the Company, such as to repay debt, buy back common stock under the share repurchase program or pay dividends.

     

    Management reviews and analyzes net sales by geographical location and by products on a consolidated basis. The Company currently sells its products in three regions: (i) the Americas (the United States, Canada and Mexico); (ii) Europe/the Middle East/Africa (“EMEA”) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden and the United Kingdom); and (iii) Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Hong Kong, Taiwan, Thailand and China). It also ships products to customers in the following countries: Belgium, France, Greece, Italy, Luxembourg, and Poland.

     

    Consolidated net sales shipped to customers in these regions, along with associate fee and product information for the three and nine months ended September 30, were as follows (in millions, except percentages):

     

      

    Three Months Ended

      

    Nine Months Ended

     
      

    September 30,

      

    September 30,

     

    Region

     

    2025

      

    2024

      

    2025

      

    2024

     

    Americas

     $7.9   27.1% $10.6   33.4% $25.1   30.8% $30.4   34.2%

    Asia/Pacific

      18.8   64.4%  18.6   58.7%  49.5   60.8%  51.6   58.0%

    EMEA

      2.5   8.5%  2.5   7.9%  6.8   8.4%  6.9   7.8%

    Total sales

     $29.2   100.0% $31.7   100.0% $81.4   100.0% $88.9   100.0%

     

     

      

    Three Months Ended

      

    Nine Months Ended

     
      

    September 30,

      

    September 30,

     
      

    2025

      

    2024

      

    2025

      

    2024

     

    Product sales

     $28.7  $31.3  $79.9  $87.3 

    Associate fees

      0.1   0.1   0.3   0.4 

    Other

      0.4   0.3   1.2   1.2 

    Total sales

     $29.2  $31.7  $81.4  $88.9 

     

    20

    Table of Contents
    MANNATECH, INCORPORATED AND SUBSIDIARIES
    NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
     

                  Long-lived assets, which include property and equipment and construction in process for the Company and its subsidiaries, as of September 30, 2025 and December 31, 2024, reside in the following regions, as follows (in millions):

     

    Region

     

    September 30, 2025

      

    December 31, 2024

     

    Americas

     $2.6  $2.4 

    Asia/Pacific

      0.6   0.5 

    EMEA

      —   — 

    Total long-lived assets

     $3.2  $2.9 

     

    Inventory balances, which consist of raw materials, finished goods, and promotional materials, as offset by the allowance for slow moving or obsolete inventories, reside in the following regions (in millions):

     

    Region

     

    September 30, 2025

      

    December 31, 2024

     

    Americas

     $6.2  $6.0 

    Asia/Pacific

      3.9   3.7 

    EMEA

      1.0   0.7 

    Total inventory

     $11.1  $10.4 

     

    The following table presents the Company's segment revenue, segment expenses and segment income (loss) for the three and nine months ended September 30, 2025 and 2024 (in thousands):

     

      

    Three Months Ended

      

    Nine Months Ended

     
      

    September 30,

      

    September 30,

     
      

    2025

      

    2024

      

    2025

      

    2024

     

    Net Sales

     $29,161  $31,725  $81,403  $88,858 

    Less:

                    

    Cost of sales

      6,890   8,105   20,495   20,763 

    Commissions and incentives

      11,192   12,893   31,312   36,237 

    Human Resources

      3,817   4,354   12,441   14,051 

    Distribution and warehouse

      474   634   1,394   1,861 

    Selling and administrative expenses

      4,520   4,482   15,198   14,207 

    Depreciation and amortization

      261   370   832   1,174 

    Interest expense

      136   166   410   334 

    Interest income

      (32)  (57)  (131)  (138)

    Other (income) expense

      (611)  1,495   2,551   (495)

    Income tax expense (benefit)

      590   (389)  819   636 

    Segment net income (loss)

     $1,924  $(328) $(3,918) $228 
                     

    Reconciliation of profit or loss

                    

    Adjustments and reconciling items

      —   —   —   — 

    Consolidated net income (loss)

     $1,924  $(328) $(3,918) $228 

     

    21

    Table of Contents
    MANNATECH, INCORPORATED AND SUBSIDIARIES
    NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
        
     

    NOTE 11: EARNINGS PER SHARE

     

    The Company calculates basic Earnings per Share ("EPS") by dividing net income by the weighted-average number of common shares outstanding for the period. Diluted EPS also reflects the potential dilution that could occur if common stock were issued for awards outstanding under the Mannatech, Incorporated 2017 Stock Incentive Plan (described above).

     

    In determining the potential dilutive effect of outstanding stock options for the three and nine months ended September 30, 2025, the Company used the quarterly and nine-month average common stock close price of  $8.64 and $9.97 per share, respectively.

     

    For the three months ended  September 30, 2025, there were 1.90 million weighted-average common shares outstanding used for the basic EPS calculation. For the three months ended September 30, 2025, 8,187 restricted stock units granted (see Note 5, Stock Based Compensation, for more information) were excluded from the calculation of diluted EPS because the related market condition was not achieved and the grant lapsed. In addition, 180,974 shares underlying stock options were excluded from the diluted EPS calculation, as their effect would have been antidilutive.

     

    For the nine months ended September 30, 2025, the Company's common stock subject to options were excluded from the diluted EPS calculation as their effect would have been antidilutive. The Company reported a net loss for the nine months ended September 30, 2025.

     

    In determining the potential dilutive effect of outstanding stock options for the three and nine months ended September 30, 2024, the Company used the quarterly and nine-month average common stock close price of $7.32 and $8.01 per share, respectively.

     

    For the three months ended September 30, 2024, the Company's common stock subject to options were excluded from the diluted EPS calculations as their effect would have been antidilutive. The Company reported a net loss for the three months ended September 30, 2024.

     

    For the nine months ended September 30, 2024, there were 1.89 million weighted-average common shares outstanding used for the basic EPS calculation. For the nine months ended September 30, 2024, 8,187 restricted stock units was granted (see Note 5, Stock Based Compensation, for more information). These shares were excluded from the calculation of diluted EPS because the related market condition was not achieved. In addition, 156,661 shares underlying stock options were excluded from the diluted EPS calculation, as their effect would have been antidilutive.

     

    Calculation of net EPS— basic and diluted (in thousands, except EPS):

     

      

    Three Months Ended

      

    Nine Months Ended

     
      

    September 30,

      

    September 30,

     
      

    2025

      

    2024

      

    2025

      

    2024

     

    Net (loss) earnings attributable to common stockholders

     $1,924  $(328) $(3,918) $228 

    Weighted average common shares outstanding (for basic calculation)

      1,901   1,885   1,901   1,885 

    Dilutive effect of outstanding common stock options and RSU’s

      —   —   —   — 

    Weighted average common and common equivalent shares outstanding

      1,901   1,885   1,901   1,885 

    EPS - Basic

     $1.01  $(0.17) $(2.06) $0.12 

    EPS - Diluted

     $1.01  $(0.17) $(2.06) $0.12 
     

     

    22

    Table of Contents
        
     

    Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations

     

    The following discussion is intended to assist in the understanding of our consolidated financial position and results of operations for the three and nine months ended September 30, 2025 as compared to the same period in 2024 and should be read in conjunction with Item 1 “Financial Statements” in Part I of this quarterly report on Form 10-Q and Item 1A “Risk Factors” in Part I of our 2024 Annual Report. Unless stated otherwise, all financial information presented below, throughout this report, and in the condensed consolidated financial statements and related notes includes Mannatech and all of our subsidiaries on a consolidated basis. To supplement our financial results presented in accordance with GAAP, we disclose certain adjusted financial measures which we refer to as Constant dollar (“Constant dollar”) measures, which are non-GAAP financial measures. Refer to the Non-GAAP Financial Measures section herein for a description of how such Constant dollar measures are determined.

     

    COMPANY OVERVIEW

     

    The Company is a global wellness solution provider, which was incorporated and began operations in November 1993. We develop and sell innovative, high quality, proprietary nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. We currently sell our products in three regions: (i) the Americas (the United States, Canada and Mexico); (ii) Europe/the Middle East/Africa (“EMEA”) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden and the United Kingdom); and (iii) Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Thailand, Hong Kong, Taiwan and China). We also ship our products to customers in the following countries: Belgium, France, Greece, Italy, Luxembourg, and Poland.

     

    We sell our products principally through network marketing distribution channels via our active associates (“independent associate” or “associates” or “distributors”) and to our “preferred customers,” which we believe is the most cost-effective way to introduce our products and communicate information about our business to the global marketplace quickly and effectively. Network marketing minimizes upfront costs, as compared to conventional marketing methods, and allows us to be more responsive to the ever-changing overall market conditions, as well as continue to research and develop high quality products and focus on controlled successful international expansion. We believe the network marketing channel also allows us to effectively communicate the potential benefits and unique properties of our proprietary products to our consumers. In addition, network marketing provides our associates with an avenue to supplement their income by building their own business centered on our business philosophies and unique products. As of September 30, 2025, we had approximately 119,000 active associates and preferred customer positions held by individuals that purchased our products and/or paid associate fees during the last twelve months. At the time of purchase, a customer may choose to sign up as a “preferred customer” to receive the same pricing on our products as our associates and to receive emails about our products and promotions. Preferred customers do not participate in the Company’s compensation plan.

     

    The Company also operates a non-direct selling business in mainland China. In 2016, we formed our China subsidiary, Meitai Daily Necessities & Health Products Co., Ltd. (“Meitai”). Unlike Mannatech’s business operations in other markets, Meitai operates under a cross-border e-commerce model, where consumers in China can buy Mannatech products manufactured overseas via Meitai’s website. Currently, Meitai is not a direct selling company in China nor can it operate under a multi-level marketing model in China. Products purchased on Meitai’s website are for personal use and not for resale. Meitai offers a rewards program to incentivize existing customers to refer other customers to purchase products from Meitai’s website. Customs regulations in China include purchase limits to ensure that purchased products are for personal consumption.

     

    Our common stock trades on The Nasdaq Capital Markets (“Nasdaq”) under the symbol “MTEX.”

     

    The Company maintains a corporate website at www.mannatech.com.

     

    Overview of Operating Results

     

    Consolidated net sales for the three months ended September 30, 2025 was $29.2 million, as compared to $31.7 million for the three months ended September 30, 2024, a decrease of $$2.6 million, or 8.1%. Consolidated net sales for the nine months ended September 30, 2025 was $81.4 million, as compared to $88.9 million for the nine months ended September 30, 2024, a decrease of $7.5 million, or 8.4%. The decline in revenues was principally due to slowing demand in certain regions we operate within, however sales for the third quarter of 2025 were higher than the first two quarters of 2025.

     

    Net realized and unrealized foreign currency gains for the three months ended September 30, 2025 was $0.6 million. For the three months ended September 30, 2024 foreign currency loss was $1.5 million.

     

    Net realized and unrealized foreign currency loss for the nine months ended September 30, 2025 was $2.6 million. For the nine months ended September 30, 2024 foreign currency gains was $0.5 million.

     

    Net income was $1.9 million for the three months ended September 30, 2025, or $1.01 per diluted share, as compared to a net loss of $0.3 million, or $0.17 per diluted share for the three months ended September 30, 2024.

     

    Net loss was $3.9 million for the nine months ended September 30, 2025, or $2.06 per diluted share, as compared to net income of $0.2 million, or $0.12 per diluted share for the nine months ended September 30, 2024. Net realized and unrealized foreign currency loss of $2.6 million contributed to overall net loss for the nine months ended September 30, 2025.

     

    23

    Table of Contents

     

    RESULTS OF OPERATIONS

     

    Three Months Ended September 30, 2025 Compared to Three Months Ended September 30, 2024

     

    The table below summarizes our consolidated operating results in dollars and as a percentage of net sales for the three months ended September 30, 2025 and 2024 (in thousands, except percentages):

     

                                       

    Change from

     
       

    2025

       

    2024

       

    2024 to 2025

     
       

    Total

       

    % of

       

    Total

       

    % of

                     
       

    dollars

       

    net sales

       

    dollars

       

    net sales

       

    Dollar

       

    Percentage

     

    Net sales

      $ 29,161       100.0 %   $ 31,725       100.0 %   $ (2,564 )     (8.1 )%

    Cost of sales

        6,890       23.6 %     8,105       25.5 %     (1,215 )     (15.0 )%

    Gross profit

        22,271       76.4 %     23,620       74.5 %     (1,349 )     (5.7 )%
                                                     

    Operating expenses:

                                                   

    Commissions and incentives

        11,192       38.4 %     12,893       40.6 %     (1,701 )     (13.2 )%

    Selling and administrative expenses

        9,072       31.1 %     9,840       31.0 %     (768 )     (7.8 )%

    Total operating expenses

        20,264       69.5 %     22,733       71.7 %     (2,469 )     (10.9 )%

    Income from operations

        2,007       6.9 %     887       2.8 %     1,120       126.3 %

    Interest expense, net

        (104 )     (0.4 )%     (109 )     (0.3 )%     5       (4.6 )%

    Other income (expense), net

        611       2.1 %     (1,495 )     (4.7 )%     2,106       (140.9 )%

    Income (loss) before income taxes

        2,514       8.6 %     (717 )     (2.3 )%     3,231       (450.6 )%

    Income tax (expense) benefit

        (590 )     (2.0 )%     389       1.2 %     (979 )     (251.7 )%

    Net income (loss)

      $ 1,924       6.6 %   $ (328 )     (1.0 )%   $ 2,252       (686.6 )%

     

    Nine Months Ended September 30, 2025 Compared to Nine Months Ended September 30, 2024

     

    The table below summarizes our consolidated operating results in dollars and as a percentage of net sales for the nine months ended September 30, 2025 and 2024 (in thousands, except percentages):

     

                                       

    Change from

     
       

    2025

       

    2024

       

    2024 to 2025

     
       

    Total

       

    % of

       

    Total

       

    % of

                     
       

    dollars

       

    net sales

       

    dollars

       

    net sales

       

    Dollar

       

    Percentage

     

    Net sales

      $ 81,403       100.0 %   $ 88,858       100.0 %   $ (7,455 )     (8.4 )%

    Cost of sales

        20,495       25.2 %     20,763       23.4 %     (268 )     (1.3 )%

    Gross profit

        60,908       74.8 %     68,095       76.6 %     (7,187 )     (10.6 )%
                                                     

    Operating expenses:

                                                   

    Commissions and incentives

        31,312       38.5 %     36,237       40.8 %     (4,925 )     (13.6 )%

    Selling and administrative expenses

        29,865       36.7 %     31,293       35.2 %     (1,428 )     (4.6 )%

    Total operating expenses

        61,177       75.2 %     67,530       76.0 %     (6,353 )     (9.4 )%

    (Loss) income from operations

        (269 )     (0.3 )%     565       0.6 %     (834 )     (147.6 )%

    Interest expense, net

        (279 )     (0.3 )%     (196 )     (0.2 )%     (83 )     42.3 %

    Other (expense) income, net

        (2,551 )     (3.1 )%     495       0.6 %     (3,046 )     (615.4 )%

    (Loss) income before income taxes

        (3,099 )     (3.8 )%     864       1.0 %     (3,963 )     (458.7 )%

    Income tax expense

        (819 )     (1.0 )%     (636 )     (0.7 )%     (183 )     28.8 %

    Net (loss) income

      $ (3,918 )     (4.8 )%   $ 228       0.3 %   $ (4,146 )     (1818.4 )%

     

    24

    Table of Contents

     

    Non-GAAP Financial Measures

     

    To supplement our financial results presented in accordance with GAAP, we disclose operating results that have been adjusted to exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, including changes in: Net Sales, Gross Profit, and Income from Operations. We refer to these adjusted financial measures as Constant dollar items, which are non-GAAP financial measures. We believe these measures provide investors an additional perspective on trends and our operating results. To exclude the impact of changes due to the translation of foreign currencies into U.S. dollars in the current year, we calculate current year results at a constant exchange rate utilizing the prior year’s rate. Currency impact is determined as the difference between the actual GAAP results and the recalculated results for the current year at the Constant dollar rates.

     

    For the three and nine months ended September 30, 2025, our net sales decreased $2.3 million and $5.8 million, or 7.3% and 6.5% on a Constant dollar basis, respectively (see reconciliation of Non-GAAP Financial Measures in the tables below); and unfavorable foreign exchange caused a $0.2 million and $1.7 million decrease in GAAP net sales as compared to the same periods in 2024, respectively.

     

    A reconciliation non-GAAP financial measures to GAAP results for the three and nine months ended September 30, 2025 and 2024 is presented as follows (in millions, except percentages):

     

    Three-month period ended

     

    September 30, 2025

       

    September 30, 2024

       

    Constant $ Change

     
       

    GAAP

               

    Non-GAAP

       

    GAAP

                     
       

    Measure:

       

    Translation

       

    Measure:

       

    Measure:

                     
       

    Total $

       

    Adjustment

       

    Constant $

       

    Total $

       

    Dollar

       

    Percent

     

    Net sales

      $ 29.2     $ 0.2     $ 29.4     $ 31.7     $ (2.3 )     (7.3 )%

    Gross profit

      $ 22.3     $ 0.1     $ 22.4     $ 23.6     $ (1.2 )     (5.1 )%

    Income from operations

      $ 2.0     $ 0.1     $ 2.1     $ 0.9     $ 1.2       133.3 %

     

     

    Nine-month period ended

     

    September 30, 2025

       

    September 30, 2024

       

    Constant $ Change

     
       

    GAAP

               

    Non-GAAP

       

    GAAP

                     
       

    Measure:

       

    Translation

       

    Measure:

       

    Measure:

                     
       

    Total $

       

    Adjustment

       

    Constant $

       

    Total $

       

    Dollar

       

    Percent

     

    Net sales

      $ 81.4     $ 1.7     $ 83.1     $ 88.9     $ (5.8 )     (6.5 )%

    Gross profit

      $ 60.9     $ 1.4     $ 62.3     $ 68.1     $ (5.8 )     (8.5 )%

    (Loss) income from operations

      $ (0.3 )   $ 0.5     $ 0.2     $ 0.6     $ (0.4 )     (66.7 )%

     

    Net Sales by Region

     

    Operations outside of the Americas accounted for approximately 72.9% of our consolidated net sales in the three months ended September 30, 2025, as compared to 66.6% in the same period last year. Operations outside of the Americas accounted for approximately 69.2% of our consolidated net sales in the nine months ended September 30, 2025, as compared to 65.8% in the same period last year.

     

    Consolidated net sales by region for the three months ended September 30, 2025 and 2024 were as follows (in millions, except percentages):

     

       

    Three Months Ended

       

    Three Months Ended

     

    Region

     

    September 30, 2025

       

    September 30, 2024

     

    Americas

      $ 7.9       27.1 %   $ 10.6       33.4 %

    Asia/Pacific

        18.8       64.4 %     18.6       58.7 %

    EMEA

        2.5       8.5 %     2.5       7.9 %

    Total

      $ 29.2       100.0 %   $ 31.7       100.0 %

     

    25

    Table of Contents

     

    Consolidated net sales by region for the nine months ended September 30, 2025 and 2024 were as follows (in millions, except percentages):

     

       

    Nine Months Ended

       

    Nine Months Ended

     

    Region

     

    September 30, 2025

       

    September 30, 2024

     

    Americas

      $ 25.1       30.8 %   $ 30.4       34.2 %

    Asia/Pacific

        49.5       60.8 %     51.6       58.0 %

    EMEA

        6.8       8.4 %     6.9       7.8 %

    Total

      $ 81.4       100.0 %   $ 88.9       100.0 %

     

    For the three months ended September 30, 2025, net sales in the Americas decreased by $2.7 million, or 25.5%, to $7.9 million, as compared to $10.6 million for the same period in 2024. The number of active independent associates and preferred customers decreased by 13.0%. There was a 14.4% decrease in revenue per active independent associate and preferred customer. Foreign currency had no effect on revenue for the three months ended September 30, 2025 when compared to the same period in 2024. 

     

    For the nine months ended September 30, 2025, net sales in the Americas decreased by $5.3 million, or 17.4%, to $25.1 million, as compared to $30.4 million for the same period in 2024. The number of active independent associates and preferred customers decreased by 12.5%. There was a 5.1% decrease in revenue per active independent associate and preferred customer. Foreign currency had the effect of decreasing revenue by $0.3 million for the nine months ended September 30, 2025 when compared to the same period in 2024. The currency impact is primarily due to the weakening of the Mexican Peso.

     

    For the three months ended September 30, 2025, Asia/Pacific net sales increased by $0.2 million, or 1.1%, to $18.8 million, as compared to $18.6 million for the same period in 2024. There was a 20.8% increase in revenue per active independent associate and preferred customer, which was partially offset by a 16.3% decrease in the number of active independent associates and preferred customers. Foreign currency exchange had the effect of decreasing revenue by $0.3 million for the three months ended September 30, 2025, as compared to the same period in 2024. The currency impact is primarily due to the weakening of the Korean Won.

     

    For the nine months ended September 30, 2025, Asia/Pacific net sales decreased by $2.1 million, or 4.1%, to $49.5 million, as compared to $51.6 million for the same period in 2024. The number of active independent associates and preferred customers decreased by 12.7%, which was partially offset by a 14.7% increase in revenue per active independent associate and preferred customer. Foreign currency exchange had the effect of decreasing revenue by $1.5 million for the nine months ended September 30, 2025, as compared to the same period in 2024. The currency impact is primarily due to the weakening of the Korean Won.

     

    For the three months ended September 30, 2025, EMEA net sales remained constant at $2.5 million, as compared to the same period in 2024. There was a 1.8% increase in revenue per active independent associate and preferred customer, which was partially offset by a 1.7% decrease in the number of active independent associates and preferred customers. Foreign currency exchange had the effect of increasing revenue by $0.1 million for the three months ended September 30, 2025 as compared to the same period in 2024. The currency impact is primarily due to the strengthening of the South African Rand.

     

    For the nine months ended September 30, 2025, EMEA net sales decreased by $0.1 million, or 1.4%, to $6.8 million, as compared to $6.9 million for the same period in 2024. The decrease was primarily due to a 4.4% decrease in the number of active independent associates and preferred customers, which was partially offset by a 0.3% increase in revenue per active independent associate and preferred customer. Foreign currency exchange had the effect of increasing revenue by $0.1 million for the nine months ended September 30, 2025 as compared to the same period in 2024. The currency impact is primarily due to the strengthening of the South African Rand.

     

    Sales Mix

     

    Our sales mix for the three and nine months ended September 30, was as follows (in millions, except percentages):

     

    Three-month period ended

     

    September 30, 2025

       

    September 30, 2024

       

    Constant $ Change

     
       

    GAAP

               

    Non-GAAP

       

    GAAP

                     
       

    Measure:

       

    Translation

       

    Measure:

       

    Measure:

                     
       

    Total $

       

    Adjustment

       

    Constant $

       

    Total $

       

    Dollar

       

    Percent

     

    Product

      $ 28.7     $ 0.2     $ 28.9     $ 31.3     $ (2.4 )     (7.7 )%

    Associate fees

        0.1       —       0.1       0.1       —       0.0 %

    Other

        0.4       —       0.4       0.3       0.1       33.3 %

    Total sales

      $ 29.2     $ 0.2     $ 29.4     $ 31.7     $ (2.3 )     (7.3 )%

     

    26

    Table of Contents

     

    Nine-month period ended

     

    September 30, 2025

       

    September 30, 2024

       

    Constant $ Change

     
       

    GAAP

               

    Non-GAAP

       

    GAAP

                     
       

    Measure:

       

    Translation

       

    Measure:

       

    Measure:

                     
       

    Total $

       

    Adjustment

       

    Constant $

       

    Total $

       

    Dollar

       

    Percent

     

    Product

      $ 79.9     $ 1.7     $ 81.6     $ 87.3     $ (5.7 )     (6.5 )%

    Associate fees

        0.3       —       0.3       0.4       (0.1 )     (25.0 )%

    Other

        1.2       —       1.2       1.2       —       0.0 %

    Total sales

      $ 81.4     $ 1.7     $ 83.1     $ 88.9     $ (5.8 )     (6.5 )%

     

     

    Product Sales

     

    Our product sales consist primarily of sales made to our independent associates and preferred customers at published wholesale prices. Product sales for the three months ended September 30, 2025 decreased by $2.6 million, or 8.3%, as compared to the same period in 2024. On a Constant dollar basis, product sales for the three months ended September 30, 2025 decreased  $0.2 million, or 0.7% , as compared to the same period in 2024. The decrease in product sales for the three months ended September 30, 2025 reflects a 5.6% decrease in the average order value to $168, as compared to $178 for the same period in 2024 and a  4.5% decrease in the number of orders processed.

     

    Product sales for the nine months ended September 30, 2025 decreased by $7.4 million, or 8.5%, as compared to the same period in 2024. On a Constant dollar basis, product sales for the nine months ended September 30, 2025 declined $1.7million, or 2.1%, as compared to the same period in 2024. The decrease in product sales for the nine months ended September 30, 2025 reflects an 8.2% decrease in the average order value to $157, as compared to $171 for the same period in 2024 and a 1.3% decrease in the number of orders processed.

     

    Associate Fees and Recruiting

     

    Recruitment of new independent associates and preferred customers decreased by 21.9% to 13,078 in the third quarter of 2025, as compared with 16,741 in the third quarter of 2024. We attribute the lower number of orders processed in the three months ended September 30, 2025 to a combination of the lower number of new independent associates and preferred customers recruited during the period.

     

    Associate fees are closely related to recruiting and retention of business-building associates. The approximate number of new and continuing active independent associates and preferred customers who purchased our products or paid associate fees during the twelve months ended September 30, 2025 and 2024 were as follows:

     

       

    2025

       

    2024

     

    New

        55,000       46.2 %     68,000       50.0 %

    Continuing

        64,000       53.8 %     68,000       50.0 %

    Total

        119,000       100.0 %     136,000       100.0 %

     

    The Company collects associate fees in certain markets. Associate fees are paid annually by new and continuing associates to the Company, which entitle them to earn commissions, benefits and incentives for that year. The Company collected associate fees within the United States, Canada, South Africa, Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, the Netherlands, Norway, Spain, Sweden the United Kingdom. Japan, Australia, New Zealand, Singapore, Hong Kong, and Taiwan.

     

    In the Republic of Korea and Mexico, packs may still be purchased by our associates who wish to build a Mannatech business, but associate fees are not sold as a standalone item. These packs contain products that are discounted from both the published retail and associate prices. There are several pack options available to our associates. In certain of these markets, pack sales are completed during the final stages of the registration process and can provide new associates with valuable training and promotional materials, as well as products for resale to retail customers, demonstration purposes, and personal consumption. Business-building associates in these markets can also purchase an upgrade pack, which provides the associate with additional promotional materials.

     

    For each of the three months ended September 30, 2025 and 2024, associate fees were $0.1 million.

     

    For the nine months ended September 30, 2025 and 2024, associate fees were $0.3 million and $0.4 million, respectively.

     

    We do not collect associate fees or sell packs in our non-direct selling business in mainland China.

     

    27

    Table of Contents

     

    Other Sales

     

    Other sales consisted of: (i) sales of promotional materials; (ii) monthly fees collected for the Success Tracker™ and Mannatech+ customized electronic business-building and educational materials, databases and applications; (iii) training and event registration fees; and (iv) a reserve for estimated sales refunds and returns. Promotional materials, training, database applications and business management tools support our independent associates, which in turn helps stimulate product sales.

     

    For the three months ended September 30, 2025 and 2024, other sales were $0.4 million and $0.3 million, respectively.

     

    For each of the nine months ended September 30, 2025 and 2024, other sales were $1.2 million.

     

    Gross Profit

     

    For the three months ended September 30, 2025, gross profit decreased by $1.3million, or 5.7%, to $22.3 million, as compared to $23.6 million for the same period in 2024. For the three months ended September 30, 2025, gross profit as a percentage of net sales increased to 76.4%, as compared to 74.5% for the same period in 2024. The increase in gross profit as a percentage of net sales was primarily due to higher sales prices which was added in the third quarter of 2025 and lower inventory reserve additions compared to the same period in 2024. The timing of certain sales promotions also increased gross profit as a percentage of net sales during the third quarter of 2025, as compared to the same period in 2024.

     

    For the nine months ended September 30, 2025, gross profit decreased by $7.2 million, or 10.6%, to $60.9 million, as compared to $68.1 million for the same period in 2024. For the nine months ended September 30, 2025, gross profit as a percentage of net sales decreased to 74.8%, as compared to 76.6% for the same period in 2024. The decrease in gross profit in dollar terms is principally due to increased product costs, including inventory markdowns, and increased freight costs. 

     

    Commissions and Incentives

     

    Commission expense for the three months ended September 30, 2025 decreased by 10.7%, or $1.3 million, to $10.9 million, as compared to $12.2 million for the same period in 2024. Commissions are earned on sales. Commission expense in dollar terms decreased during the three months ended September 30, 2025 primarily due to a decline in our sales. For the three months ended September 30, 2025, commissions as a percentage of net sales decreased to 37.5% as compared to 38.3% for the same period in 2024.

     

    Commission expense for the nine months ended September 30, 2025 decreased by 11.6%, or $4.0 million, to $30.5 million, as compared to $34.5 million for the same period in 2024. Commissions are earned on sales. Commission expense in dollar terms decreased during the nine months ended September 30, 2025 primarily due to a decline in our sales. For the nine months ended September 30, 2025, commissions as a percentage of net sales decreased to 37.4% as compared to 38.8% for the same period in 2024.

     

    Incentive costs for the three months ended September 30, 2025 and 2024 decreased to $0.2 million, as compared to $0.7 million for the same period in 2024. For the three months ended September 30, 2025, incentives as a percentage of net sales decreased to 0.9% as compared to 2.3% for the same period in 2024.

     

    Incentive costs for the nine months ended September 30, 2025 and 2024 decreased to $0.8 million, as compared to $1.8 million for the same period in 2024. For the nine months ended September 30, 2025, incentives as a percentage of net sales decreased to 1.0% as compared to 2.0% for the same period in 2024.

     

    28

    Table of Contents

     

    Selling and Administrative Expenses

     

    Selling and administrative expenses include a combination of both fixed and variable expenses. These expenses consist of compensation and benefits for employees; temporary and contract labor; accounting, legal and consulting fees; compensation to our board of directors; warehouse and fulfillment costs; depreciation and amortization; marketing-related expenses; travel and entertainment expenses; credit card processing fees; costs for software maintenance agreements; insurance; charitable contributions; office lease expense; utilities; bad debt; and other miscellaneous operating expenses.

     

    For the three months ended September 30, 2025, selling and administrative expenses decreased by $0.7 million, or 7.8%, to $9.1 million, as compared to $9.8 million for the same period in 2024. The decrease in selling and administrative expenses was the result of a $0.4 million reduction in payroll costs, a $0.1 million decrease in travel and entertainment costs, a $0.1 million decrease in warehouse costs and a $0.1 million decrease in charitable contributions. Selling and administrative expenses, as a percentage of net sales, for the three months ended September 30, 2025 increased to 31.1% from 31.0% for the same period in 2024.

     

    For the nine months ended September 30, 2025, selling and administrative expenses decreased by $1.4 million, or 4.6%, to $29.9 million, as compared to $31.3 million for the same period in 2024. The decrease in selling and administrative expenses was the result of a $1.7 million decrease in payroll costs, a $0.5 million decrease in warehouse costs and a $0.1 million decrease in charitable contributions, which was offset by a $0.3 million increase in marketing costs, a $0.3 million increase in office expenses and a $0.3 million increase in legal and consulting fees. Selling and administrative expenses, as a percentage of net sales, for the nine months ended September 30, 2025 increased to 36.7% from 35.2% for the same period in 2024.

     

    Other Income (Expense), Net

     

    Foreign exchange gains were $0.6million for the three months ended September 30, 2025. Foreign exchange losses were $1.5 million for the three months ended September 30, 2024.

     

    Foreign exchange losses were $2.6 million for the nine months ended September 30, 2025. Foreign exchange gains were $0.5 million for the nine months ended September 30, 2024.

     

    Income Tax (Provision) Benefit

     

    Income tax expense was $0.6 million for the three months ended September 30, 2025 as compared to income tax benefit of $0.4 million in the same period in 2024. Income tax expense for the nine months ended September 30, 2025 and 2024 was $0.8 million and $0.6 million, respectively.

     

    Income tax (provision) or benefit includes current and deferred income taxes for both our domestic and foreign operations. Our statutory income tax rates for key jurisdictions are as follows, for the nine months ended September 30,:

     

    Country

     

    2025

       

    2024

     

    China(1)

        25.0 %     25.0 %

    Hong Kong

        16.5 %     16.5 %

    Japan

        34.6 %     34.6 %

    Republic of Korea

        20.9 %     20.9 %

    United States(2)

        22.2 %     22.2 %

     

    (1) For 2025, the Company qualified for a reduced tax rate of 5% in China as a Small Low Profit Enterprise.

    (2) Includes blended state effective rate of 1.2% for 2025 and 2024 in addition to U.S. federal statutory rate of 21%.

     

    Income from our international operations is subject to taxation in the countries in which we operate. Although we may receive foreign income tax credits that would reduce the total amount of income taxes owed in the United States, we may not be able to fully utilize our foreign income tax credits in the United States.

     

    We use the recognition and measurement provisions of the FASB ASC Topic 740, Income Taxes (“Topic 740”), to account for income taxes. The provisions of Topic 740 require a company to record a valuation allowance when the “more likely than not” criterion for realizing net deferred tax assets cannot be met. Furthermore, the weight given to the potential effect of such evidence should be commensurate with the extent to which it can be objectively verified. As a result, we reviewed the operating results, as well as all of the positive and negative evidence related to realization of such deferred tax assets to evaluate the need for a valuation allowance in each tax jurisdiction.

     

    The provision for income taxes is directly related to our profitability and changes in the taxable income across countries of operation. For the three and nine months ended September 30, 2025, the Company’s effective tax rate was 23.5% and (26.4)%, respectively. For the three and nine months ended September 30, 2024, the Company's effective tax rate was 54.3% and 73.6%, respectively.

     

    The effective tax rates for the three and nine months ended September 30, 2025 and 2024 was different from the federal statutory rate due primarily to the mix of earnings across jurisdictions and the associated valuation allowances recorded on losses in certain jurisdictions.

     

    29

    Table of Contents

     

    LIQUIDITY AND CAPITAL RESOURCES

     

    Cash and Cash Equivalents

     

    As of September 30, 2025, our cash and cash equivalents decreased by 37.3%, or $4.3 million, to $7.1 million from $11.4 million as of December 31, 2024. The Company is required to restrict cash for: (i) direct selling insurance premiums and credit card sales in the Republic of Korea; (ii) reserves related to credit card sales in the United States and Canada; and (iii) collateral for a building lease in Australia. The current portion of restricted cash balances was $0.6 million at each of September 30, 2025 and December 31, 2024. The long-term portion of restricted cash balances was $0.2 million and $0.6 million at September 30, 2025 and December 31, 2024

     

    Our principal use of cash is to pay for operating expenses, including commissions and incentives, capital assets, inventory purchases, and periodic cash dividends. We did not pay a dividend in the current quarter. Business objectives, operations, and expansion of operations are funded through net cash flows from operations rather than incurring long-term debt.

     

    Working Capital

     

    Working capital represents total current assets less total current liabilities. At September 30, 2025 and December 31, 2024, our working capital was $2.6 million and $5.2 million, respectively.

     

    Net Cash Flows

     

    Our net consolidated cash flows consisted of the following, for the nine months ended September 30, (in millions):

     

    Provided by (Used in):

     

    2025

       

    2024

     

    Operating activities

      $ (2.7 )   $ 2.5  

    Investing activities

      $ (1.2 )   $ (0.4 )

    Financing activities

      $ (0.3 )   $ 2.9  

     

    Operating Activities

     

    Operating activities used $2.7 million cash for the nine months ended September 30, 2025 as compared to cash provided of $2.5 million for the same period in 2024.

     

    Investing Activities

     

    For the nine months ended September 30, 2025 and 2024, we invested cash of $1.2 million and $0.4 million, respectively, principally for back-office software projects, reported as property and equipment.

     

    Financing Activities

     

    For the nine months ended September 30, 2025, our financing activities used cash of $0.3 million. For the nine months ended September 30, 2025, we used $0.3 million in the repayment of finance lease obligations.

     

    For the nine months ended September 30, 2024, our financing activities provided cash of $2.9 million. We received $3.6 million from the issuance of notes payable (see Note 4) and we used $0.7 million in the repayment of finance lease obligations.

     

    30

    Table of Contents

     

    General Liquidity and Cash Flows

     

    Short Term Liquidity

     

    As of September 30, 2025, our cash and cash equivalents was $7.1 million. We believe our existing liquidity and cash flows from operations are adequate to fund our normal expected future business operations for the next twelve months.

     

    On April 23, 2024, the Company entered into unsecured Loan and Promissory Note agreements with three related parties, who are members of the Company’s Board of Directors, and who are current stockholders of the Company, in an aggregate principal amount of $3.6 million. The purpose of the borrowing was to provide funds to the Company for general working capital needs, including payment to vendors, expansion of the Company’s non-US operations, technology investment primarily for improving the customer ordering process and software updates to improve visibility of sales associate activity. On September 9, 2025, the Company entered into loan extension agreements extending the maturity date of the notes from September 30, 2026, to March 31, 2027.  All other terms of the notes remained unchanged.

     

    We have operating lease liabilities for the property and equipment we use in our business operations. These operating lease liabilities represent our minimum future payment obligations on operating leases, including imputed interest. At September 30, 2025, our operating lease liabilities were $4.4 million, of which $1.7 million is presented as the current portion and $2.7 million is presented as Operating lease liabilities excluding current portion on our Condensed Consolidated Balance Sheets. We also have finance lease liabilities of $0.8 million and lease restoration liabilities of $0.3 million.

     

    As our primary source of liquidity has historically been our cash flows from operations, our liquidity is dependent on our ability to maintain and/or continue to improve revenue as compared to our operational expenses. In this regard, our management has established a business reorganization plan focusing on revenue growth, margin improvement and cost control and reduction, including a plan to improve margin through a price increase, continued focus on supply chain costs, and certain compensation plan adjustments, as well as to reorganize certain functional operations and reduce our fixed selling and administrative overhead.

     

    However, if our reorganization plans are not successful, or if we experience further or unexpected disruption in our supply chain, and/or potential decreases in consumer demands, our sales and our overall liquidity in the next twelve months could be negatively impacted. If our existing capital resources or cash flows become insufficient to meet current business plans, projections, and existing capital requirements, we may be required to raise additional funds, which may not be available on favorable terms, if at all.

     

    Long Term Liquidity

     

    We believe our cash flows from operations should be adequate to fund our normal expected future business operations and possible international expansion costs for the long term. As our primary source of liquidity is from our cash flows from operations, this will be dependent on our ability to maintain or improve revenue as compared to operational expenses.

     

    However, if our existing capital resources or cash flows become insufficient to meet anticipated business plans and existing capital requirements, we may be required to raise additional funds, which may not be available on favorable terms, if at all.

     

    Our future access to the capital markets may be adversely impacted if we fail to maintain compliance with the Nasdaq Marketplace Rules for the continued listing of our stock. We continuously monitor our compliance with the Nasdaq continued listing rules.

     

    31

    Table of Contents

     

    OFF-BALANCE SHEET ARRANGEMENTS

     

    We do not have any special-purpose entity arrangements, nor do we have any off-balance sheet arrangements.

     

    CRITICAL ACCOUNTING ESTIMATES

     

    Our condensed consolidated financial statements are prepared in accordance with GAAP. The application of GAAP requires us to make estimates and assumptions that affect the reported values of assets and liabilities at the date of our financial statements, the reported amounts of revenues and expenses during the reporting period, and the related disclosures of contingent assets and liabilities. We use estimates throughout our financial statements, which are influenced by management’s judgment and uncertainties. Our estimates are based on historical trends, industry standards, and various other assumptions that we believe are applicable and reasonable under the circumstances at the time the condensed consolidated financial statements are prepared. Our Audit Committee reviews our significant accounting policies and critical estimates. We continually evaluate and review our policies related to the portrayal of our consolidated financial position and consolidated results of operations that require the application of significant judgment by our management. We also analyze the need for certain estimates, including the need for such items as allowance for credit losses, inventory reserves, long-lived fixed assets and capitalization of internal-use software development costs, reserve for uncertain income tax positions and tax valuation allowances, revenue recognition, sales returns, and deferred revenues, accounting for stock-based compensation, and contingencies and litigation. Historically, actual results have not materially deviated from our estimates. However, we caution readers that actual results could differ from our estimates and assumptions applied in the preparation of our condensed consolidated financial statements. If circumstances change relating to the various assumptions or conditions used in our estimates, we could experience an adverse effect on our financial position, results of operations, and cash flows. We have identified the following applicable significant accounting policies and critical estimates as of September 30, 2025.

     

    Inventory Reserves

     

    Inventory consists of raw materials, finished goods, and promotional materials that are stated at the lower of cost (using standard costs that approximate average costs) or net realizable value. We record the amounts charged by the vendors as the costs of inventory. Typically, the net realizable value of our inventory is higher than the aggregate cost. Determination of net realizable value can be complex and, therefore, requires a high degree of judgment. In order for management to make the appropriate determination of net realizable value, the following items are considered: inventory turnover statistics, current selling prices, seasonality factors, consumer demand, regulatory changes, competitive pricing, and performance of similar products. If we determine the carrying value of inventory is in excess of estimated net realizable value, we write down the value of inventory to the estimated net realizable value.

     

    We also review inventory for obsolescence in a similar manner and any inventory identified as obsolete is reserved or written off. Our determination of obsolescence is based on assumptions about the demand for our products, product expiration dates, estimated future sales, and general future plans. We monitor actual sales compared to original projections, and if actual sales are less favorable than those originally projected by us, we record an additional inventory reserve or write-down. Historically, our estimates have been close to our actual reported amounts. However, if our estimates regarding inventory obsolescence are inaccurate or consumer demand for our products changes in an unforeseen manner, we may be exposed to additional material losses or gains in excess of our established estimated inventory reserves.

     

    Tax Valuation Allowances

     

    As of September 30, 2025, there was nothing recorded in other long-term liabilities on our condensed consolidated balance sheet related to uncertain income tax positions. As required by Topic 740, we use judgments and make estimates and assumptions related to evaluating the probability of uncertain income tax positions. We base our estimates and assumptions on the potential liability related to an assessment of whether the income tax position will “more likely than not” be sustained in an income tax audit. We are also subject to periodic audits from multiple domestic and foreign tax authorities related to income tax and other forms of taxation. These audits examine our tax positions, timing of income and deductions, and allocation procedures across multiple jurisdictions. Depending on the nature of the tax issue, we could be subject to audit over several years. There are ongoing income tax audits in various international jurisdictions that we believe are not material to our financial statements.

     

    32

    Table of Contents

     

    Revenue Recognition and Deferred Commissions

     

    Our revenue is derived from sales of individual products and associate fees or, in certain geographic markets, starter packs. Substantially all of our product sales are to associates and preferred customers at published wholesale prices. We record revenue net of any sales taxes and record a reserve for expected sales returns based on historical experience. The Company changed its shipping terms with customers such that ownership transfers upon delivery to the freight carrier, satisfying the Company's performance obligation. Previously, the Company's shipping terms were FOB destination, so the Company recognized revenue upon delivery of the product to the customer. Corporate-sponsored event revenue is recognized when the event is held.

     

    Orders placed by associates or preferred customers constitute our contracts. Product sales placed in the form of an automatic order contain two performance obligations: (1) the sales of the product and (2) the loyalty program. For these contracts, we account for each of these obligations separately as they are each distinct. The transaction price is allocated between the product sale and the loyalty program on a relative standalone selling price basis. Sales placed through a one-time order contain only the first performance obligation noted above – the sale of the product.

     

    We provide associates with access to a complimentary three-month package for the Success Tracker™ and Mannatech+ online business tools with the first payment of an associate fee. The first payment of an associate fee contains three performance obligations: (1) providing new associates with the eligibility to earn commissions, bonuses and incentives for twelve months, (2) three months of complimentary access to utilize the Success Tracker™ online tool, and (3) three months of complimentary access to utilize the Mannatech+ online business tool. The transaction price is allocated between the three performance obligations on a relative standalone selling price basis. Associates do not have complimentary access to online business tools after the first contractual period.

     

    With regard to both of the aforementioned contracts, we determine the standalone selling prices by using observable inputs, which include our standard published price lists.

     

    Product Return Policy

     

    We stand behind our products and believe we offer a reasonable and industry-standard product return policy to all of our customers. We do not resell returned products. Refunds are not processed until proper approval is obtained. All refunds must be processed and returned in the same form of payment that was originally used in the sale. Each country in which we operate has specific product return guidelines. However, we allow our associates and preferred customers to exchange products as long as the products are unopened and in good condition. Our return policies for our retail customers and our associates and preferred customers are as follows:

     

     

    •

    Retail Customer Product Return Policy. This policy allows a retail customer to return any of our products to the original associate who sold the product and receive a full cash refund from the associate for the first 180 days following the product’s purchase if located in the United States and Canada, and for the first 90 days following the product’s purchase in other countries where we sell our products. The associate may then return or exchange the product based on the associate product return policy.

     

     

    •

    Associate and Preferred Customer Product Return Policy. This policy allows the associate or preferred customer to return an order within one year of the purchase date upon terminating his/her account. If an associate or preferred customer returns a product unopened and in good condition, he/she may receive a full refund minus a 10% restocking fee. We may also allow the associate or preferred customer to receive a full satisfaction guarantee refund if they have tried the product and are not satisfied for any reason, excluding promotional materials. This satisfaction guarantee refund applies in the United States and Canada, only for the first 180 days following the product’s purchase and applies in other countries where we sell our products for the first 90 days following the product’s purchase; however, any commissions earned by an associate will be deducted from the refund. If we discover abuse of the refund policy, we may terminate the associate’s or preferred customer’s account.

     

    Historically, sales returns estimates have not materially deviated from actual sales returns, as the majority of our customers who return merchandise do so within the first 90 days after the original sale. Based upon our return policies and historical experience, we estimate a sales return reserve for expected sales refunds over a rolling six-month period. If actual results differ from our estimated sales returns reserves due to various factors, the amount of revenue recorded each period could be materially affected. Historically, our sales returns have not materially changed through the years and have averaged 0.5% or less of our gross sales.

     

    33

    Table of Contents

     

    Item 3.   Quantitative and Qualitative Disclosures About Market Risk

     

    We do not engage in trading market risk sensitive instruments and do not purchase investments as hedges or for purposes “other than trading” that are likely to expose us to certain types of market risk, including interest rate, commodity price, or equity price risk. Although we have investments, we believe there has been no material change in our exposure to interest rate risk. We have not issued any debt instruments, entered into any forward or futures contracts, purchased any options, or entered into any swap agreements.

     

    We are exposed, however, to other market risks, including changes in currency exchange rates as measured against the United States dollar. Because the change in value of the United States dollar measured against foreign currency may affect our consolidated financial results, changes in foreign currency exchange rates could positively or negatively affect our results as expressed in United States dollars. For example, when the United States dollar strengthens against foreign currencies in which our products are sold or weakens against foreign currencies in which we may incur costs, our consolidated net sales or related costs and expenses could be adversely affected. We translate our revenues and expenses in foreign markets using an average rate.

     

    We maintain policies, procedures, and internal processes in an effort to help monitor any significant market risks and we do not use any financial instruments to manage our exposure to such risks. We assess the anticipated foreign currency working capital requirements of our foreign operations and maintain a portion of our cash and cash equivalents denominated in foreign currencies sufficient to satisfy most of these anticipated requirements.

     

    We caution that we cannot predict with any certainty our future exposure to such currency exchange rate fluctuations or the impact, if any, such fluctuations may have on our future business, product pricing, operating expenses, and on our consolidated financial position, results of operations, or cash flows. However, to combat such market risk, we closely monitor our exposure to currency fluctuations.

     

    Item 4.   Controls and Procedures

     

    Evaluation of Disclosure Controls and Procedures

     

    Our management, with the participation of our Chief Executive Officer (principal executive officer) and our Chief Financial Officer (principal financial officer), have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures (as defined in Rule 13a-15(e) or Rule 15d-15(e) under the Exchange Act) are effective to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and include controls and procedures designed to ensure that information required to be disclosed by us in such reports is accumulated and communicated to our management, including our principal executive and financial officers, as appropriate, to allow timely decisions regarding required disclosure.

     

    Changes in Internal Control over Financial Reporting

     

    During the quarter ended September 30, 2025, there were no changes in our internal control over our financial reporting that we believe materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

     

    34

    Table of Contents
     

     

    PART II - OTHER INFORMATION

    Item 1.   Legal Proceedings

     

    See Note 7, Litigation, of our Notes to Unaudited Condensed Consolidated Financial Statements, which is incorporated herein by reference.

     

    Item 1A. Risk Factors

     

    Our profitability and market competitiveness may be adversely impacted by changes in trade policies, including tariffs or other factors.

     

    Changes in trade policies, including the imposition of new tariffs or increases in existing tariffs between the United States, Mexico, Canada, China, South Korea or other countries, or reactionary measures including retaliatory tariffs, legal challenges, or currency manipulation, could adversely affect our cost structure and profitability. If tariffs on imported materials, components, or finished goods increase, our manufacturing and supply chain costs may rise. Furthermore, changes to trade policies, retaliatory measures, or prolonged uncertainty in trade relationships could result in supply chain disruptions, delayed shipments, or increased operational complexity, adversely affecting our business and financial results. While we take steps to mitigate or avoid these increased costs and disruptions, our ability to do so may be limited by operational and supply chain constraints and uncertainties, especially in the short term. In addition, our ability to recover cost increases and maintain profitability levels through price adjustments may be limited by competitive pressures, customer acceptance, and contractual limitations.

     

    International trade disputes, geopolitical tensions, and military conflicts have led, and continue to lead, to new and increasing export restrictions, trade barriers, tariffs, and other trade measures that can increase our manufacturing and transportation costs, limit our ability to sell to certain customers or markets, limit our ability to procure, or increase our costs for, components or raw materials, impede or slow the movement of our goods across borders, or otherwise restrict our ability to conduct operations. Increasing protectionism, economic nationalism, and national security concerns may also lead to further changes in trade policy. We work closely with our manufacturing partners to implement ways to mitigate the impact of these tariffs on our supply chain as promptly and reasonably as practicable, including shifting production outside of areas where tariffs could increase our costs. We cannot predict what further actions may be taken with respect to export regulations, tariffs or other trade regulations between the United States and other countries, what products or companies may be subject to such actions, or what actions may be taken by other countries in retaliation. In addition, actions to mitigate the effect of these tariffs are disruptive on our operations, may not be completely successful and may result in higher long-term manufacturing costs. Moreover, there is no certainty that countries to which we have shifted our manufacturing operations will not be subject to similar tariffs in the future. As a result, we may be required to raise our prices on certain products, which could result in the loss of customers and harm to our revenue, market share, competitive position and operating performance.

     

    In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our 2024 Annual Report, which could materially affect our business or our consolidated financial position, results of operations, and cash flows. The risks described in our 2024 Annual Report are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be insignificant also may become materially adverse or may affect our business in the future or our consolidated financial position, results of operations, or cash flows.

     

    Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds

     

    None.

     

    Item 3.   Defaults Upon Senior Securities

     

    None.

     

    Item 4.   Mine Safety Disclosures

     

    Not Applicable.

     

     

    Item 5.   Other Information

     

    Not Applicable.

        

     

    Item 6    Exhibits

     

    See Index to Exhibits immediately following this page.

     

    35

    Table of Contents

     

    INDEX TO EXHIBITS

     

           

    Incorporated by Reference

    Exhibit

    Number

     

    Exhibit Description

     

    Form

     

    File No.

     

    Exhibit (s)

     

    Filing Date

    3.1

     

    Amended and Restated Articles of Incorporation of Mannatech, Incorporated, dated May 19, 1998.

     

    S-1

     

    333-63133

     

    3.1

     

    September 10, 1998

    3.2

     

    Amendment to the Amended and Restated Articles of Incorporation of Mannatech, dated January 13, 2012.

     

    8-K

     

    000-24657

     

    3.1

     

    January 17, 2012

    3.3

     

    Fifth Amended and Restated Bylaws of Mannatech, dated August 25, 2014.

     

    8-K

     

    000-24657

     

    3.1

     

    August 27, 2014

    4.1

     

    Specimen Certificate representing Mannatech’s common stock, par value $0.0001 per share.

     

    S-1

     

    333-63133

     

    4.1

     

    October 28, 1998

    10.17

     

    Loan Agreement and Promissory Note with Jade Capital, signed April 23, 2024.

     

    8-K

     

    000-24657

     

    10.2

     

    April 23, 2024

    10.18

     

    Loan Agreement and Promissory Note with J. Stanley Fredrick, signed April 23, 2024.

     

    8-K

     

    000-24657

     

    10.2

     

    April 23, 2024

    10.19

     

    Loan Agreement and Promissory Note with Kevin Robbins, signed April 23, 2024.

     

    8-K

     

    000-24657

     

    10.2

     

    April 23, 2024

    31.1**

     

    Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, of the Chief Executive Officer of Mannatech.

     

    *

     

    *

     

    *

     

    *

    31.2**

     

    Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, of the Chief Financial Officer of Mannatech.

     

    *

     

    *

     

    *

     

    *

    32.1**

     

    Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of the Chief Executive Officer of Mannatech.

     

    **

     

    **

     

    **

     

    **

    32.2**

     

    Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of the Chief Financial Officer of Mannatech.

     

    **

     

    **

     

    **

     

    **

    101.INS*

     

    Inline XBRL Instance Document

     

    *

     

    *

     

    *

     

    *

    101.SCH*

     

    Inline XBRL Taxonomy Extension Schema Document

     

    *

     

    *

     

    *

     

    *

    101.CAL*

     

    Inline XBRL Taxonomy Extension Calculation Linkbase Document

     

    *

     

    *

     

    *

     

    *

    101.LAB*

     

    Inline XBRL Taxonomy Extension Label Linkbase Document

     

    *

     

    *

     

    *

     

    *

    101.PRE*

     

    Inline XBRL Taxonomy Extension Presentation Linkbase Document

     

    *

     

    *

     

    *

     

    *

    101.DEF*

     

    Inline XBRL Taxonomy Extension Definition Linkbase Document

     

    *

     

    *

     

    *

     

    *

    104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)                

     

     

    *

    Filed herewith.

     

    **

    Furnished herewith.

     

     

    36

    Table of Contents

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

    MANNATECH, INCORPORATED

       

    Dated: November 12, 2025

    By:

    /s/ Landen Fredrick

       

    Landen Fredrick

       

    Chief Executive Officer

       

    (principal executive officer)

     

    Dated: November 12, 2025

    By:

    /s/ James Clavijo

       

    James Clavijo

       

    Chief Financial Officer

       

    (principal financial officer)

     

     

     

    37
    Get the next $MTEX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTEX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTEX
    SEC Filings

    View All

    Mannatech Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MANNATECH INC (0001056358) (Filer)

    11/12/25 4:05:07 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Mannatech Incorporated

    10-Q - MANNATECH INC (0001056358) (Filer)

    11/12/25 4:03:53 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - MANNATECH INC (0001056358) (Filer)

    9/12/25 4:22:20 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rameson Tyler bought $126,232 worth of shares (16,288 units at $7.75), increasing direct ownership by 6% to 299,197 units (SEC Form 4)

    4 - MANNATECH INC (0001056358) (Issuer)

    9/10/24 5:45:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by Chief Financial Officer Clavijo James

    4/A - MANNATECH INC (0001056358) (Issuer)

    8/28/25 4:22:11 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form 4 filed by General Counsel Barta Erin Kemmler

    4/A - MANNATECH INC (0001056358) (Issuer)

    8/28/25 4:22:03 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form 4 filed by President and CEO Fredrick Landen Granvel

    4/A - MANNATECH INC (0001056358) (Issuer)

    8/28/25 4:21:55 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mannatech Reports Financial Results for Third Quarter 2025

    FLOWER MOUND, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2025. Third Quarter Results Net sales for the quarter ended September 30, 2025 were $29.2 million, as compared to $31.7 million for the same period in 2024, a decrease of $2.6 million, or 8.1%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $2.3 million, or 7.3%, and unfavorable foreign exchange caused a $0.2 million decrease in GAAP net sales as compared to the same period in 2024. Th

    11/12/25 4:02:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Reports Financial Results for Second Quarter 2025

    Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2025. Second Quarter Results Net sales for the quarter ended June 30, 2025 were $25.7 million, as compared to $27.7 million for the same period in 2024, a decrease of $2.1 million, or 7.4%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.8 million, or 6.5%, and unfavorable foreign exchange caused a $0.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

    8/12/25 5:18:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Announces Promotion of Peter Griscom to Chief Operating Officer

    Mannatech, Incorporated (NASDAQ: MTEX) announces the promotion of Peter Griscom to Chief Operating Officer of Mannatech Incorporated (the "Company") effective July 1, 2025. Peter Griscom brings more than 10 years of experience in the direct selling channel and has extensive experience in working in the consumer goods space, including launching, leading, and restructuring companies while creating efficiencies in manufacturing, sales, and marketing. Prior to his promotion, Mr. Griscom served as the Company's senior vice president of global operations since August 21, 2024 and prior to that served as the senior vice president of product, innovation, & supply chain from July 3, 2023 through A

    6/26/25 2:11:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Leadership Updates

    Live Leadership Updates

    View All

    Mannatech Announces Results of Annual Shareholders' Meeting

    Mannatech, Incorporated (Nasdaq: MTEX) ("Mannatech"), a global health and wellness company committed to transforming lives to make a better world, announced that its shareholders passed all proposals put to a vote at Mannatech's annual shareholder meeting (the "Meeting") held Tuesday, June 3, 2025. Mannatech's Chairman of the Board, J. Stanley Fredrick, chaired the Meeting, and James Clavijo, Mannatech's Chief Financial Officer, spoke to the shareholders sharing the company's financial results for 2024. There were 1,900,930 outstanding shares of Mannatech's common stock as of April 8, 2025 entitled to vote and 1,478,342 shares, or approximately 77.8% represented at the Meeting, either i

    6/5/25 2:30:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of Directors

    Mannatech, Incorporated (NASDAQ: MTEX) announced that on November 20, 2024, the Board of Directors of Mannatech, Incorporated (the "Board") appointed Robert A. Toth to the Board where he will serve as Vice Chairman of the Board of Mannatech, Incorporated (the "Company") effective December 1, 2024. Mr. Toth will serve as a Class III director of the Board. Mr. Toth previously served on the Company's Board between March 2008 through May 31, 2023. Mr. Toth previously served as the Chairman of the Compensation and Stock Option Plan Committee, served on the Audit Committee, the Nominating/Governance and Compliance Committee, the Science and Marketing Committee, and from August 2014 to March 201

    11/26/24 4:30:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

    Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c

    7/1/24 5:46:00 PM ET
    $AEZS
    $MTEX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    $MTEX
    Financials

    Live finance-specific insights

    View All

    Mannatech Reports Financial Results for Third Quarter 2025

    FLOWER MOUND, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2025. Third Quarter Results Net sales for the quarter ended September 30, 2025 were $29.2 million, as compared to $31.7 million for the same period in 2024, a decrease of $2.6 million, or 8.1%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $2.3 million, or 7.3%, and unfavorable foreign exchange caused a $0.2 million decrease in GAAP net sales as compared to the same period in 2024. Th

    11/12/25 4:02:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Reports Financial Results for Second Quarter 2025

    Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2025. Second Quarter Results Net sales for the quarter ended June 30, 2025 were $25.7 million, as compared to $27.7 million for the same period in 2024, a decrease of $2.1 million, or 7.4%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.8 million, or 6.5%, and unfavorable foreign exchange caused a $0.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

    8/12/25 5:18:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Reports Financial Results for First Quarter 2025

    Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2025. First Quarter Highlights Net sales for the quarter ended March 31, 2025 were $26.6 million, as compared to $29.4 million for the same period in 2024, a decrease of $2.8 million, or 9.6%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.6 million, or 5.4%, and unfavorable foreign exchange caused a $1.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

    5/13/25 6:06:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Mannatech Incorporated

    SC 13G - MANNATECH INC (0001056358) (Subject)

    11/1/24 11:44:29 AM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

    SC 13G/A - MANNATECH INC (0001056358) (Subject)

    1/13/23 11:03:46 AM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

    SC 13G/A - MANNATECH INC (0001056358) (Subject)

    2/7/22 6:32:28 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care